Short peptide compounds as well as preparation method therefor and medical use thereof

By developing compounds that specifically inhibit APP2 and increase bradykinin levels, the problem of reperfusion injury after vascular recanalization was solved, achieving a protective therapeutic effect against ischemic stroke and acute myocardial infarction.

WO2024230583A1PCT designated stage expired Publication Date: 2024-11-14SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/090822
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-07
Filing Date
2024-04-30
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing treatments for ischemic stroke and acute myocardial infarction are prone to reperfusion injury after vascular recanalization, and there is a lack of effective drugs to improve cellular metabolic disorders and structural damage.

Method used

An APP2 inhibitor that specifically inhibits ACE, NEP, aminopeptidase P and carboxypeptidases M/N enzymes was developed to reduce reperfusion injury by increasing bradykinin levels. The compound of formula (I) and its optical isomers or pharmaceutically acceptable salts were used to prepare drugs for treating diseases related to APP2 activity.

Benefits of technology

It effectively reduces reperfusion injury in ischemic stroke and acute myocardial infarction, improves infarct volume and cerebral edema, and protects nerve cell function. It can be used to treat ischemic stroke, acute myocardial infarction, chronic heart failure, myocardial hypertrophy and other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024090822_14112024_PF_FP_ABST
    Figure CN2024090822_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Short peptide compounds as well as a preparation method therefor and the medical use thereof. Specifically, disclosed are compounds represented by formula (I), optical isomers thereof, or pharmaceutically acceptable salts thereof.
Need to check novelty before this filing date? Find Prior Art

Description

A short peptide compound and its preparation method and medical application

[0001] The present invention claims the following priority:

[0002] 1) Application number CN 202310500394.6, application date May 5, 2023;

[0003] 2) Application number CN 202311087670.7, application date August 25, 2023;

[0004] 3) Application number CN 202311477989.0, application date November 7, 2023. Technical Field

[0005] The present invention belongs to the field of medicinal chemistry, and in particular relates to a short peptide compound, a preparation method thereof, and medical applications thereof. Background Art

[0006] Stroke is a clinically defined syndrome of acute, focal neurological deficits caused by vascular injury (infarction, hemorrhage) in the central nervous system. In recent years, stroke has become the second leading cause of death and disability worldwide.

[0007] Stroke is generally categorized as hemorrhagic or ischemic, presenting with headache, dizziness, speech impairment, sensory and motor impairments in the limbs, and impairments in memory, emotion, and even consciousness. In 2019, the most common stroke types worldwide were ischemic stroke, hemorrhagic stroke, and subarachnoid hemorrhage, accounting for 62.4%, 27.9%, and 9.7%, respectively.

[0008] Currently, there are two main strategies for treating ischemic stroke: one is to improve blood supply, including intravenous thrombolysis, intravascular intervention, antiplatelet therapy, and anticoagulant therapy; the other is to protect the structure and function of nerve cells. Intravenous thrombolysis is currently one of the most important measures to restore cerebral blood flow in patients with acute ischemic stroke.

[0009] Acute myocardial infarction (AMI) is a sudden blockage of a coronary artery, leading to insufficient blood supply to the myocardium and ischemia or necrosis of myocardial cells. The vast majority of AMIs are caused by arterial thrombosis. The most important treatment for AMI is to re-open the infarcted vessels. There are two common approaches to this: stent implantation and thrombolysis.

[0010] For ischemic stroke and acute myocardial infarction, although vascular recanalization is an indispensable treatment, reperfusion itself can also cause damage during the process. After blood reperfusion is restored, some patients' cell functional metabolic disorders and structural damage are aggravated. Currently, there is no drug that can specifically improve clinical ischemia-reperfusion injury.

[0011] Studies have shown that bradykinin can reduce infarct size in both tMCAO and acute myocardial infarction models in rats, demonstrating a protective effect against ischemia-reperfusion. Bradykinin degradation in the human body is primarily regulated by enzymes including ACE, NEP, aminopeptidase P, and carboxypeptidases M / N. Approximately 30% of bradykinin is degraded by APP2, which has high substrate specificity and can specifically cleave the arginine at the N-terminus of bradykinin. Therefore, by inhibiting APP2 activity, it is possible to increase bradykinin levels and thus reduce reperfusion injury.

[0012] Existing studies have shown that specific APP2 inhibitors can improve infarct volume and brain edema in rat tMCAO models and significantly reduce myocardial infarction size in mouse myocardial infarction models. Therefore, the development of small molecule inhibitors targeting APP2 has potential therapeutic value for ischemic stroke and reperfusion-induced damage in acute myocardial infarction.

[0013] Summary of the Invention

[0014] In one aspect of the present invention, the present invention provides a compound represented by formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof,

[0015] in,

[0016] R1 is selected from C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted with 1, 2 or 3 R;

[0017] R2 is selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted with 1, 2 or 3 R;

[0018] R3 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R;

[0019] R4 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R;

[0020] R5 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R;

[0021] R6 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R;

[0022] R7 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R;

[0023] Alternatively, R6 and R7 are connected together to form a C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 R;

[0024] R8 is selected from H or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R groups;

[0025] Alternatively, R6 and R8 are connected together to form a bridge ring;

[0026] R9 is selected from H, halogen or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R groups;

[0027] R 10 Selected from H, halogen, OH, CN, NH2 or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R groups;

[0028] Or, R9 and R 10 Connect together to form a C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 R;

[0029] R 11 Selected from H, D or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R groups;

[0030] Or, R1 and R 11 Connect together to form a C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R;

[0031] R 12 Selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted with 1, 2 or 3 R;

[0032] L1 is selected from a single bond or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R;

[0033] L2 is selected from a single bond or -(CH2) n -, the -(CH2) n-optionally substituted with 1 or 2 R;

[0034] L3 is selected from a single bond or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R;

[0035] L4 is selected from a single bond, -O- or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R;

[0036] L5 is selected from a single bond, -C(=O)-, -C(=O)-(CH2) n -or-(CH2) n -, said -C(=O)-(CH2) n - and -(CH2) n -optionally substituted with 1 or 2 R;

[0037] L6 is selected from a single bond or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R;

[0038] n is independently selected from 0, 1, 2, 3, 4, 5 or 6;

[0039] R is independently selected from H, F, Cl, Br, OH, NH2, CN, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio and C 1-6 Alkylamino, the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino is optionally substituted with 1, 2 or 3 R';

[0040] R' is selected from F, Cl, Br, I, OH, NH2 and CH3;

[0041] The above C 1-6 The heteroalkyl or 5-10 membered heteroaryl group contains 1, 2 or 3 heteroatoms or heteroatom groups independently selected from -O-, -NH-, -S-, -C(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2- and N.

[0042] In some embodiments of the present invention, the above R is selected from H, F, Cl, Br, OH, NH2, COOH, Me, CF3, CHF2, CH2F, Other variables are as defined in the present invention.

[0043] In some embodiments of the present invention, the above R1 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are optionally substituted with 1, 2 or 3 R, and the other variables are as defined herein.

[0044] In some embodiments of the present invention, the above R1 is selected from Me, Other variables are as defined in the present invention.

[0045] In some embodiments of the present invention, the above-mentioned L1 is selected from a single bond, -CH2- or -CH2CH2-, and the -CH2- and -CH2CH2- are optionally substituted by 1 or 2 R, and other variables are as defined in the present invention.

[0046] In some embodiments of the present invention, the above L1 is selected from a single bond, -CH2- or -CH2CH2-, and other variables are as defined in the present invention.

[0047] In some embodiments of the present invention, the above structural unit Selected from Me, Other variables are as defined in the present invention.

[0048] In some embodiments of the present invention, the above L2 is selected from a single bond, -CH2- or -CH2CH2-, and the -CH2- and -CH2CH2- are optionally substituted by 1 or 2 R;

[0049] L3 is selected from a single bond, -CH2- or -CH2CH2-, wherein -CH2- and -CH2CH2- are optionally substituted with 1 or 2 R, and other variables are as defined herein.

[0050] In some embodiments of the present invention, the above-mentioned L2 is selected from a single bond, -CH2- or -CH2CH2-;

[0051] L3 is selected from a single bond, -CH2- or -CH2CH2-, and other variables are as defined herein.

[0052] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0053] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0054] In some embodiments of the present invention, the above L4 is selected from a single bond, -O- or -CH2-, and other variables are as defined in the present invention.

[0055] In some embodiments of the present invention, the above structural unit Selected from Other variables are as defined in the present invention.

[0056] In some embodiments of the present invention, the above R 11 is selected from H, D or Me, and the other variables are as defined in the present invention.

[0057] In some embodiments of the present invention, the above R1 and R 11 are linked together to form a cyclopropane group, and the other variables are as defined in the present invention.

[0058] The present invention also provides a compound of the following formula, an optical isomer thereof or a pharmaceutically acceptable salt thereof, which is selected from

[0059] In another aspect of the present invention, the present invention also provides the use of the aforementioned compound, its optical isomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating diseases related to APP2 activity or bradykinin.

[0060] In some embodiments of the present invention, the above-mentioned APP2 activity or bradykinin-related diseases are selected from ischemic stroke, acute myocardial infarction, chronic heart failure, myocardial hypertrophy, diabetic microangiopathy, renal hypertension, diabetic nephropathy, renal ischemia-reperfusion injury, drug-induced renal injury, chronic kidney disease, atherosclerosis, vascular restenosis, etc.

[0061] In some embodiments of the present invention, the above-mentioned chronic kidney disease is selected from polycystic kidney disease, IgA nephropathy, etc.

[0062] Definition and Description

[0063] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be construed as indefinite or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.

[0064] As used herein, the phrase "at least one" when referring to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows that elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers may optionally be present, whether related or unrelated to those specifically identified elements.

[0065] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0066] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, prepared by reacting the compounds of the present invention with relatively nontoxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in neat solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts, or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, bisulfate, hydroiodic acid, phosphorous acid, and the like; and organic acid salts such as acetic acid, propionic acid, isobutyric acid, trifluoroacetic acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; and salts of amino acids (such as arginine) and organic acids such as glucuronic acid. Certain specific compounds of the present invention contain both basic and acidic functional groups and can be converted into either base or acid addition salts.

[0067] Pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture thereof.

[0068] "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, formulation aid, or vehicle commonly used in the art with therapeutic agents to form a "pharmaceutical composition" for administration to a subject. A pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration employed and is compatible with the other ingredients of the formulation. The pharmaceutically acceptable carrier is appropriate for the formulation being employed.

[0069] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permitted only if such combinations result in stable compounds. For example, Can be selected from wait.

[0070] A hyphen ("-") that is not between two letters or symbols indicates the site of attachment of a substituent. For example, C 1-6 Alkylcarbonyl - refers to a C-alkyl group attached to the rest of the molecule through a carbonyl group. 1-6 However, when the attachment point of the substituent is obvious to those skilled in the art, for example, a halogen substituent, the "-" may be omitted.

[0071] When the group valence bond is marked with a dotted line When, for example, In the example, the dashed line represents the point of attachment of the group to the rest of the molecule.

[0072] The term "substituted" or "substituted with" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, including deuterium and hydrogen variants, as long as the valence state of the particular atom is normal and the substituted compound is stable. The term "optionally substituted" or "optionally substituted with" means that the atom may or may not be substituted. Unless otherwise specified, the type and number of substituents may be any based on chemical practicability.

[0073] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 1, 2, or 3 R's, the group may optionally be substituted with 1, 2, or 3 R's, with each occurrence of R' being an independent choice. Furthermore, combinations of substituents and / or their variants are permitted only if such combinations result in stable compounds.

[0074] When one of the variables is selected from a single bond, it means that the two groups it connects are directly connected, such as When L1 represents a single bond, it means that the structure is actually

[0075] When the substituents listed do not specify through which atom they are connected to the substituted group, such substituents can be bonded through any atom thereof. For example, a pyridyl substituent can be connected to the substituted group through any carbon atom on the pyridine ring.

[0076] When the linking group is listed without specifying its linking direction, its linking direction is arbitrary, for example, The connecting group L is -CH2O-, in which case -CH2O- can connect phenyl and cyclopentyl in the same direction as reading from left to right to form It is also possible to connect phenyl and cyclopentyl groups in the opposite direction of reading from left to right to form Combinations of linkers, substituents, and / or variations thereof are permissible only if such combinations result in stable compounds.

[0077] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

[0078] Unless otherwise specified, the number of atoms in a ring is generally defined as the ring member number, for example, a "3-6 membered ring" refers to a "ring" having 3-6 atoms arranged around it.

[0079] Unless otherwise specified, the term “C 1-6 "Alkyl" is used to represent a straight or branched chain saturated hydrocarbon group consisting of 1 to 6 carbon atoms. 1-6 Alkyl groups include C 1-5 、C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-4 , C6 and C5 alkyl, etc.; which can be monovalent (such as CH3), divalent (-CH2-) or polyvalent (such as ). C 1-6 Examples of alkyl groups include, but are not limited to, CH3, wait.

[0080] The term "heteroalkyl" by itself or in combination with another term refers to a stable straight or branched chain alkyl radical or combination thereof consisting of a certain number of carbon atoms and at least one heteroatom or heteroatom group. In some embodiments, the heteroatom is selected from B, O, N and S, wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen heteroatom is optionally quaternized. In other embodiments, the heteroatom group is selected from -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O), -S(=O)2-, -C(=O)N(H)-, -N(H)-, -C(=NH)-, -S(=O)2N(H)- and -S(=O)N(H)-. In some embodiments, the heteroalkyl group is C 1-6 In other embodiments, the heteroalkyl group is C 1-3 Heteroalkyl. The heteroatom or heteroatom group may be located at any interior position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule, but the term "alkoxy" is used conventionally to refer to those alkyl groups that are attached to the remainder of the molecule through an oxygen atom. Examples of heteroalkyl groups include, but are not limited to, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -CH2-CH2-O-CH3, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)(CH2CH3), -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH(CH3)2, -CH2-S-CH2-CH3, -CH2-CH2-S-CH3, -S(=O)-CH3, -CH2-CH2-S(=O)2-CH3, and up to two heteroatoms can be consecutive, for example, -CH2-NH-OCH3.

[0081] Unless otherwise specified, the term “C 1-6 "Alkoxy" refers to an alkyl group containing 1 to 6 carbon atoms which is attached to the rest of the molecule via an oxygen atom. 1-6 Alkoxy groups include C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-4 , C6, C5, C4 and C3 alkoxy, etc. 1-6 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexyloxy, and the like.

[0082] Unless otherwise specified, the term “C1-3 "Alkoxy" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via an oxygen atom. The C 1-3 Alkoxy groups include C 1-3 、C 1-2 、C 2-3 , C1, C2 and C3 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

[0083] Unless otherwise specified, the term “C 1-6 "Alkylamino" means an alkyl group containing 1 to 6 carbon atoms which is attached to the rest of the molecule via an amino group. 1-6 Alkylamino groups include C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-4 , C6, C5, C4, C3 and C2 alkylamino, etc. 1-6 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -N(CH2CH3)(CH2CH3), -NHCH2CH2CH3, -NHCH(CH3)2, -NHCH2CH2CH2CH3, and the like.

[0084] Unless otherwise specified, the term “C 1-3 "Alkylamino" means an alkyl group containing 1 to 3 carbon atoms which is attached to the rest of the molecule via an amino group. 1-3 Alkylamino groups include C 1-3 、C 1-2 、C 2-3 , C1, C2 and C3 alkylamino, etc. 1-3 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH(CH3)2, and the like.

[0085] Unless otherwise specified, the term “C 1-6 "Alkylthio" refers to those alkyl groups containing 1 to 6 carbon atoms which are linked to the rest of the molecule via a sulfur atom. 1-6 Alkylthio includes C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-4 , C6, C5, C4, C3 and C2 alkylthio, etc. 1-6Examples of alkylthio groups include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH(CH3)2, and the like.

[0086] Unless otherwise specified, the term “C 1-3 "Alkylthio" refers to those alkyl groups containing 1 to 3 carbon atoms which are linked to the rest of the molecule via a sulfur atom. 1-3 Alkylthio includes C 1-3 、C 1-2 、C 2-3 , C1, C2 and C3 alkylthio, etc. 1-3 Examples of alkylthio groups include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH(CH3)2, and the like.

[0087] Unless otherwise specified, “C 3-6 "Cycloalkyl" means a saturated cyclic hydrocarbon group consisting of 3 to 6 carbon atoms, which is a monocyclic or bicyclic ring system. 3-6 Cycloalkyl groups include C 3-5 、C 4-5 and C 5-6 Cycloalkyl, etc.; it may be monovalent, divalent or polyvalent. 3-6 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0088] Unless otherwise specified, the term "3-6 membered heterocyclyl" by itself or in combination with other terms means a saturated or partially unsaturated cyclic group consisting of 3 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen and sulfur atoms are independently optionally oxidized (i.e., C=O, NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spirocyclic, cyclic and bridged rings. In addition, with respect to the "3-6 membered heterocyclic group", a heteroatom may occupy the position where the heterocyclic group is connected to the rest of the molecule. The 3-6 membered heterocyclic group includes 3-6 membered, 3-5 membered, 3-4 membered, 4-5 membered, 4-6 membered, 5-6 membered, 3 membered, 4 membered, 5 membered, 6 membered heterocyclic groups and the like. Examples of 3-6 membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, 1,3-dioxolane, Pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl or homopiperidinyl, etc.

[0089] Unless otherwise specified, the term "5-6 membered heterocyclyl" by itself or in combination with other terms means a saturated or partially unsaturated cyclic group consisting of 5 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein the bicyclic ring system includes spirocyclic, fused and bridged rings. In addition, with respect to the "5-6 membered heterocyclic group", a heteroatom may occupy the position where the heterocyclic group is connected to the rest of the molecule. The 5-6 membered heterocyclic group includes 5-membered and 6-membered heterocyclic groups. Examples of 5-6 membered heterocyclic groups include, but are not limited to, 1,3-dioxolane, Pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl or homopiperidinyl, etc.

[0090] Unless otherwise specified, the terms "5-6 membered heteroaromatic ring" and "5-6 membered heteroaryl" are used interchangeably in the present invention. The term "5-6 membered heteroaryl" refers to a monocyclic group with a conjugated π electron system consisting of 5 to 6 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p, p is 1 or 2). 5-6 membered heteroaryl can be connected to the rest of the molecule through a heteroatom or a carbon atom. The 5-6 membered heteroaryl includes 5-membered and 6-membered heteroaryl. Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl) and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl and 5-thiazolyl, etc.), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl, etc.), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.).

[0091] Unless otherwise specified, the term “C 6-10 "Aryl" by itself or in combination with other terms refers to a monocyclic or bicyclic aromatic ring system having six to ten carbon atoms. Non-limiting exemplary aryl groups include phenyl (abbreviated as "Ph"), naphthyl.

[0092] Unless otherwise specified, C n-n+m or C n -C n+m Any specific case including n to n+m carbons, such as C 1-12 Including C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 、C 11 , and C 12 , also includes any range from n to n+m, such as C 1-12 Including C 1-3 、C 1-6 、C 1-9 、C 3-6 、C 3-9 、C 3-12 、C 6-9 、C 6-12 , and C 9-12etc.; similarly, n-membered to n+m-membered means that the number of atoms in the ring is n to n+m, for example, a 3-12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, and a 12-membered ring, and also includes any range from n to n+m, for example, a 3-12-membered ring includes a 3-6-membered ring, a 3-9-membered ring, a 5-6-membered ring, a 5-7-membered ring, a 5-10-membered ring, a 6-7-membered ring, a 6-8-membered ring, a 6-9-membered ring and a 6-10-membered ring, etc.

[0093] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C). For example, deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged drug biological half-life. All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of this invention.

[0094] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0095] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention.

[0096] The solvent used in the present invention is commercially available.

[0097] Compounds are named according to the conventional nomenclature in the art or using Software naming, commercially available compounds use supplier catalog names.

[0098] The compounds disclosed in the present invention may have one or more chiral centers, each of which independently has an R configuration or an S configuration, or a cis-Cis-configuration, or a trans-Trans-configuration. The chiral centers of some compounds disclosed in the present invention are marked with *R, *S, R*, S, *Cis-, or *Trans-, indicating that the absolute configuration of the chiral center of the compound has not been identified, but the compound has been separated or chirally resolved and the chiral center is a chiral center of a single configuration, and the compound is a single-configuration enantiomer monomer, or a single-configuration diastereoisomer monomer, or a diastereoisomer mixture with a single configuration of the chiral center (for example: the configuration of other chiral centers has not been resolved), or a single-configuration monomer (for example, a single cis-configuration monomer, or a single trans-configuration monomer). When the absolute configuration (R configuration, S configuration, Cis-configuration, or Trans-configuration) of the chiral center of the compound disclosed in the present invention has not been identified, such compounds can be identified based on their corresponding nuclear magnetic resonance (NMR) spectra. 1 H-NMR, 31 The peak shape in the P-NMR spectrum or the retention time (RT or Rt) corresponding to the corresponding chromatographic column conditions (such as chromatographic column model, chromatographic column filling material, chromatographic column size, mobile phase, etc.) can be confirmed.

[0099] The present invention is explained in more detail in the following examples. However, it should be understood that these examples are intended to illustrate the present invention and are not intended to limit the scope of the invention in any way. The experimental methods in the following examples, unless otherwise specified, generally follow conventional conditions for such reactions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight. Unless otherwise stated, liquid ratios are by volume.

[0100] Technical and scientific terms used herein without specific definition have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. DETAILED DESCRIPTION

[0101] The present application is described in detail below by way of examples, but this does not necessarily mean that there are any adverse limitations on the present application. The present application has been described in detail herein, and specific embodiments thereof have been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present application without departing from the spirit and scope of the present application.

[0102] Unless otherwise specified, the experimental materials and reagents used in the following examples can be obtained from commercial channels.

[0103] In all embodiments, 1 H NMR, 13 C NMR, 19 F NMR and31 P NMR spectra were recorded using a Bruker Ascend 400 MHz NMR instrument and processed using Topspin software, with deuterated solvents acting as internal deuterium locks. 13 C NMR, 19 F NMR and 31 PNMR 1 H decoupling. Assignments were made based on well-defined chemical shifts / coupling patterns or on the basis of 2D Cosy, HMBC, HSQC, or NOESY experiments. Peak multiplicities were defined as: s singlet, d doublet, t triplet, q quartet, m multiplet, br broad, br.s broad singlet; coupling constants (J) were given to the nearest 0.1 Hz. Mass spectra were recorded using an Agilent 1260 (ESI) or Shimadzu LC-MS-2020 (ESI) or Agilent 6215 (ESI) mass spectrometer; reversed-phase preparative HPLC separations were performed using an Agilent 1290 UV-guided automated purification system ( Prep C18 OBDTM 21.2*250mm 10μm column) or Gilson GX281 UV-guided automatic purification system (xBridge C18 OBDTM 19*250mm 10μm column) or Waters QDa-guided fully automated purification system (SunFire C18 OBD 29*250mm 10μm column). Unless otherwise specified, separations were performed using SepaFlash prepacked normal-phase silica gel columns (Sinopharm Chemical Reagent Co., Ltd.) and TLC analytical plates (Yantai Jiangyou Silica Gel Development Co., Ltd., model: HSGF254, size: 2.5×5cm). All eluent ratios were by volume.

[0104] The Chinese names of the reagents represented by chemical formulas or English abbreviations are as follows:

[0105] CD3OD represents deuterated methanol; DMSO-d6 represents deuterated dimethyl sulfoxide; Chloroform-d or CDCl3 represents deuterated chloroform; AcOH represents acetic acid; AlCl3 represents aluminum chloride; Aq represents aqueous solution; N2 represents nitrogen; Ar represents argon; B2Pin2 represents diboronic acid pinacol ester; BBr3 represents boron tribromide; BH3 represents borane; (Boc)2O represents di-tert-butyl dicarbonate; Et3SiH represents triethylsilane; HATU represents 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; HOBt represents 1-hydroxybenzotriazole; K2CO3 represents carbon =K2CO3 represents potassium carbonate; KOAc represents potassium acetate; MeONa represents sodium methoxide; LDA represents lithium diisopropylamide; LiHMDS represents lithium bis(trimethylsilyl)amide; LiOH represents lithium hydroxide; m-CPBA represents m-chloroperbenzoic acid; Na2CO3 represents sodium carbonate; NaBH4 represents sodium borohydride; NaCl represents sodium chloride; NaHCO3 represents sodium bicarbonate; NaOH represents sodium hydroxide; Na2SO4 represents sodium sulfate; NBS represents N-bromosuccinimide; NCS represents N-chlorosuccinimide; NIS represents N-iodosuccinimide; n-BuLi represents n-butyllithium; NH4Cl represents ammonium chloride; NMP represents N-methyl-2-pyrrolidone; PBr3 represents phosphorus tribromide; Pd(dppf)Cl2 or PdCl2(dppf) represents 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride; Pd2(dba)3 represents tris(dibenzylideneacetone)dipalladium(0); Pd(OAc)2 represents palladium acetate; conc. represents concentrated; (COCl)2 represents oxalyl chloride; Cs2CO3 represents cesium carbonate; CuCl represents cuprous chloride; CuI represents cuprous iodide; DCM represents dichloromethane; Dioxane or 1,4-dioxane represents 1,4-dioxane; MeCN, ACN or CH3CN represents acetonitrile; MeOH or methanol represents methanol; EtOH or ethanoic acid represents methanol. l represents ethanol; DEA represents diethylamine; DIPEA or DIEA represents N,N-diisopropylethylamine; DIAD represents diisopropyl azodicarboxylate; Xantphos represents 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; DMAP represents 4-dimethylaminopyridine; DMF represents N,N-dimethylformamide; DMSO represents dimethyl sulfoxide; EA or EtOAc represents ethyl acetate; PE represents petroleum ether; THF represents tetrahydrofuran; Toluene or tol. represents toluene; SOCl2 represents thionyl chloride; TFA represents trifluoroacetic acid; FA represents formic acid; TMSCN represents trimethylsilyl cyanide; H2O represents water; HCl represents hydrogen chloride gas; HCl aq.stands for aqueous hydrochloric acid; °C stands for degrees Celsius; rt or RT stands for room temperature; h stands for hour; min stands for minute; g stands for gram; mg stands for milligram; mL stands for milliliter; mmol stands for millimole; M stands for mole; cm stands for centimeter; mm stands for millimeter; μm stands for micrometer; nm stands for nanometer; mL / min stands for milliliter per minute; Hz stands for hertz; MHz stands for megahertz; bar stands for bar; psi stands for pounds per square inch; N2 stands for nitrogen; HPLC stands for high performance liquid chromatography; ID stands for inner diameter; LCMS or LC-MS stands for liquid chromatography-mass spectrometry; m / z stands for mass-to-charge ratio; ESI stands for electrospray ionization; CO2 stands for carbon dioxide; TLC stands for thin-layer chromatography; UV stands for ultraviolet; IV stands for intravenous; PO stands for oral; rpm stands for revolutions per minute; ATCC stands for American type culture collection.

[0106] Example 1: Preparation of Compound 1

[0107] Preparation of compound 1-2

[0108] Compound 1-1 (7.67 g, 46.46 mmol) was dissolved in DCM (70 mL) and cooled to 0°C in an ice-water bath. Compound 1-1a (11.67 g, 46.46 mmol) and HOBT (8.16 g, 60.39 mmol) were added. The reaction mixture was stirred at 0°C for 10 minutes, followed by the addition of DIPEA (26.72 g, 206.73 mmol) and continued stirring at this temperature for 10 minutes. Finally, EDCI (11.58 g, 60.39 mmol) was added. After stirring at 0°C for 10 minutes, the ice-water bath was removed and the reaction system was stirred at room temperature for 16 hours. The organic phase was concentrated and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 1-2 (10.0 g, 59.4% yield). LC-MS (ESI): m / z 307.2 [M+H-56] + .

[0109] Preparation of Compounds 1-3

[0110] Compound 1-2 (10.0 g, 27.6 mol) was dissolved in a 1,4-dioxane hydrochloric acid solution (4.0 M, 100 mL, 400 mmol) and stirred at room temperature for 10 minutes. The organic solvent was removed by concentration to obtain the crude title compound 1-3 (6.0 g, yield 72.8%), which was used directly in the next reaction.

[0111] Preparation of Compounds 1-4

[0112] Compound 1-3 (6.0 g, 22.87 mmol) was dissolved in DCM (60 mL) and cooled to 0°C in an ice-water bath. Compound 1-1a (5.74 g, 22.87 mmol) and HOBT (4.02 g, 29.73 mmol) were added and stirred at this temperature for 10 minutes. DIPEA (14.77 g, 114.35 mmol) was then added and stirring continued for 10 minutes. Finally, EDCI (5.69 g, 29.73 mmol) was added. After stirring at 0°C for 10 minutes, the ice-water bath was removed and the reaction system was stirred at room temperature for 16 hours. The organic phase was concentrated and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 1-4 (4.0 g, 53.0% yield). LC-MS (ESI): m / z 496.0 [M+H] + .

[0113] Preparation of Compounds 1-5

[0114] Compound 1-4 (6.0 g, 12.10 mmol) was dissolved in a 1,4-dioxane solution of hydrochloric acid (100 mL, 4 M) and stirred at room temperature for 10 minutes. The organic solvent was removed by concentration to obtain the title compound 1-5 (4.0 g, yield 76.6%).

[0115] Preparation of Compound 1-7

[0116] Compound 1-6 (20.0 g, 152.47 mmol) was dissolved in a mixed solvent of HBr (70.68 g, 491.30 mmol, 48%) and H2O (150 mL), cooled to 0°C in an ice-water bath, and slowly added dropwise a solution of NaNO2 (13.15 g, 190.59 mmol) in water (60 mL) at the same temperature, and stirred at the same temperature for 60 minutes. The ice-water bath was removed, and the reaction system was stirred at room temperature for 5 hours, extracted with EtOAc (30 mL × 3), and the organic phases were combined, washed with saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product 1-7 (10.0 g, yield 33.6%). 1 H NMR (400MHz, CDCl3) δ 11.12 (br.s, 1H), 4.30 (t, J = 7.7Hz, 1H), 1.93 (t, J = 7.3Hz, 2H), 1.81 (hept, J = 6.8Hz, 1H), 0.98 (d, J = 6.6Hz, 3H), 0.93 (d, J = 6.6Hz, 3H).

[0117] Preparation of Compound 1-8

[0118] Compound 1-7 (10.0 g, 51.26 mmol) was dissolved in DMF (50 mL), cooled to 0°C in an ice-water bath, and KSAc (11.71 g, 102.51 mmol) was added under argon protection. After addition, the mixture was stirred at 0°C for 2 hours. The pH of the solution was adjusted to about 3 with dilute aqueous hydrochloric acid (1 M), and extracted with EtOAc (30 mL × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product 1-8 (8.0 g, yield 82.1%). 1 H NMR(400MHz, CDCl3)δ10.71(br.s,1H),4.23(t,J=7.8Hz,1H),2.37(s,3H),1.91–1.79(m,1H ),1.71(hept,J=6.7Hz,1H),1.64–1.52(m,1H),0.97(d,J=6.6Hz,3H),0.92(d,J=6.6Hz,3H).

[0119] Preparation of Compound 1-9

[0120] Compound 1-5 (4.0 g, 10.12 mmol) was dissolved in DCM (50 mL) and cooled to 0°C in an ice-water bath. Compound 1-8 (1.92 g, 10.12 mmol) and HOBT (1.78 g, 13.16 mmol) were added and stirred at this temperature for 10 minutes. DIPEA (8.50 g, 65.8 mmol) was then added and stirred at this temperature for 10 minutes. Finally, EDCI (2.52 g, 13.16 mmol) was added. After stirring at 0°C for 10 minutes, the ice-water bath was removed and the reaction system was stirred at room temperature for 16 hours. The organic phase was concentrated and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 1-9 (2.0 g, 34.8% yield). LC-MS (ESI): m / z 568.1 [M+H] + .

[0121] Preparation of compound 1

[0122] Compound 1-9 (2.0 g, 3.52 mmol) was suspended in a mixed solvent of MeOH / H2O (5.0 mL / 5.0 mL) and cooled to 0°C in an ice-water bath. NaOH (704 mg, 17.60 mmol) was added under argon protection and stirred at this temperature for 10 minutes. The ice-water bath was removed and the reaction system was stirred at room temperature for 30 minutes. The reaction solution was directly adjusted to pH 3 with dilute aqueous hydrochloric acid (1 M) and purified by reverse phase C18 chromatography to obtain the title compound 1 (1.02 g, yield 56.9%). LC-MS (ESI): m / z 512.2 [M+H]+ ; 1 H NMR(400MHz,DMSO-d6)δ12.58(br.s,1H),5.00–4.60(m,2H),4.45–4.32(m,2H),4.05–3.85(m,2H),3.80–3.40(m,4H),3.18–2.86 (m,5H),2.45-2.25(m,2H),2.20-1.90(m,2H),1.75-1.55(m,2H),1.50-1.35(m,1H),0.87(d,J=6.5Hz,3H),0.84(d,J=6.5Hz,3H).

[0123] Example 2: Preparation of Compound 2

[0124] Preparation of compound 2-2

[0125] Compound 2-1 (4.0 g, 7.7 mmol) was dissolved in a mixed solution of water (30 mL) and hydrobromic acid (6.53 g, 38.71 mmol, 48% purity). The mixture was cooled to 0°C in an ice-water bath and stirred at this temperature for 30 minutes. A solution of NaNO2 (1.47 g, 95.3 mmol) in water (12 mL) was slowly added dropwise. After the addition, the mixture was stirred at 0°C for 2 hours. The ice-water bath was removed, and the mixture was gradually warmed to room temperature and stirred for another 2 hours. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The mixture was washed with saturated brine (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude title compound 2-2 (2.6 g, 43.3% yield). LC-MS (ESI): m / z 192.9 [M+H] + .

[0126] Preparation of compound 2-3

[0127] Compound 2-2 (2.6 g, 13.5 mol) was dissolved in DMF (50 mL), and KSAc (338.9 mg, 17.8 mol) was added. The mixture was allowed to react at room temperature for 12 h. After completion of the reaction, water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (100 mL × 3). The organic phase was washed with saturated aqueous ammonium chloride (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to afford the crude title compound 2-3 (1.6 g, 70.0% yield). LC-MS (ESI): m / z 189.0 [M+H] + .

[0128] Preparation of compound 2-5

[0129] Compound 2-4 (10 g, 40.1 mmol) was dissolved in DCM (100 mL), and compound 1-1 (6.62 g, 40.1 mmol), EDCI (10.0 g, 52.13 mmol), HOBt (7.0 g, 52.13 mmol), and DIPEA (2.6 g, 200.5 mmol) were added. The reaction mixture was allowed to react at room temperature for 4 hours. After completion of the reaction, the organic phase was concentrated and purified via reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 2-5 (12.5 g, 54.0% yield). LC-MS (ESI): m / z 361.0 [M+H] + .

[0130] Preparation of Compound 2-6

[0131] Compound 2-5 (3.4 g, 9.4 mmol) was dissolved in anhydrous acetonitrile (40 mL), and Pd / C (1.15 g, 0.94 mmol, 10% wt) was added. The reaction system was immediately purged with hydrogen three times, and the reaction mixture was stirred at room temperature for 8 hours. After the reaction was completed, the mixture was filtered through celite, and water (50 mL) was added to the filtrate. The mixture was extracted with DCM (50 mL × 3). The organic phases were combined, washed with saturated brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 2-6 (1.6 g, yield 75.0%). LC-MS (ESI): m / z 227.2 [M+H] + .

[0132] Preparation of compound 2-7

[0133] Compound 2-6 (400 mg, 1.8 mmol) was added to a three-necked flask, followed by anhydrous DCM (5 mL), compound 1-1a (441.2 mg, 1.8 mmol), EDCI (438.9 mg, 5.4 mmol), HOBt (310.5 mg, 5.4 mmol), and DIPEA (1.1 g, 9.0 mmol). The reaction mixture was stirred at room temperature for 12 hours. After the reaction, the solvent was concentrated and the residue was added with an appropriate amount of acetonitrile. The title compound 2-7 (450 mg, 55.4% yield) was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%). LC-MS (ESI): m / z 460.2 [M+H] + .

[0134] Preparation of compound 2-8

[0135] Compound 2-7 (300 mg, 0.65 mmol) was dissolved in acetonitrile (1 mL). A solution of hydrochloric acid in 1,4-dioxane (3 mL, 12 mmol, 4 M) was added. The reaction mixture was stirred at room temperature for 4 hours. The organic phase was concentrated to give the title compound 2-8 (210 mg, 81.6% yield). LC-MS (ESI): m / z 360.2 [M+H] + .

[0136] Preparation of compound 2-9

[0137] Compound 2-8 (200 mg, 0.6 mmol) was placed in a three-necked flask, followed by anhydrous DCM (5 mL), compound 2-3 (104.8 mg, 0.6 mmol), HATU (273.0 mg, 0.7 mmol), and DIPEA (359.6 mg, 2.8 mmol). The reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the solvent was concentrated and an appropriate amount of acetonitrile was added. The mixture was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 2-9 (75 mg, 25.4% yield). LC-MS (ESI): m / z 530.2 [M+H] + .

[0138] Preparation of compound 2

[0139] Compound 2-9 (80 mg, 0.63 mmol) was dissolved in THF (1.0 mL), and aqueous sodium hydroxide solution (2 mL, 1 M) was added. The mixture was allowed to react at room temperature for 2 hours. After completion of the reaction, dilute hydrochloric acid (1 M) was added dropwise until the pH was approximately 6-7. The product was then purified by preparative chromatography (preparative method: mobile phase: A: 0.1% formic acid aqueous solution; B: acetonitrile; column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to obtain the title compound 2 (25 mg, crude product, 73.5% yield). The crude compound 2 was purified by SFC (preparative conditions: instrument model: MG II preparative SFC (SFC-13), column model: ChiralPak IC, 250×30 mm ID, 10 μm, mobile phase: A: CO2, B: isopropanol, elution gradient: B 40%, flow rate: 80 mL / min, column pressure: 100 bar, column temperature: 38°C, wavelength: 220 nm, cycle time: ~4.5 min) to obtain purified compound 2 (15 mg). LC-MS (ESI): m / z 474.2 [M+H] +SFC analysis method (instrument model: Waters UPC2 analytical SFC (SFC-H), chromatographic column model: ChiralPak IC-3, 100×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (containing 0.05% DEA); elution gradient: B 40%; flow rate: 2.5 mL / min; column temperature: 35°C; column pressure: 100 bar; detection wavelength: 220 nm; RT = 1.461 min); 1 H NMR(400MHz,DMSO-d6)δ12.40(br.s,1H),4.88-4.79(m,1H),4.57-4.49(m,1H),4.43- 4.30(m,1H),4.03–3.86(m,1H),3.75–3.62(m,2H),3.57–3.43(m,3H),3.28–3.09(m,2H ),3.05–2.85(m,2H),2.37–2.22(m,1H),2.21–2.02(m,3H),1.99–1.87(m,3H),1.83–1. 65(m,2H),1.40–1.28(m,1H),0.90–0.70(m,1H),0.48–0.30(m,2H),0.18–0.03(m,2H).

[0140] Example 3: Preparation of Compound 3

[0141] Preparation of compound 3-1

[0142] Compound 1-5 (431 mg, 1.0 mmol) and compound 2-3 (226 mg, 1.2 mmol) were dissolved in DCM (5 mL), and HATU (566 mg, 1.5 mmol) and DIPEA (517 mg, 4.0 mmol) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 3-1 (125 mg, yield 22.1%). LC-MS (ESI): m / z 566.2 [M+H] + .

[0143] Preparation of compound 3

[0144] Compound 3-1 (113 mg, 200 μmol) was dissolved in THF (2 mL). Under nitrogen, a 1.0 M aqueous NaOH solution (1.6 mL, 1.60 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. 1 M dilute hydrochloric acid was added to adjust the pH of the solution to approximately 4-5. The organic solvent was removed by concentration and the mixture was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 3 (25 mg, yield 24.5%). LC-MS (ESI): m / z 510.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.55(br.s,1H),4.92-4.83(m,1H),4.82-4.76(m,1H),4.44-4.31(m,1H),4.00-3.88(m,2H),3.73-3 .20(m,5H),3.18-2.80(m,4H),2.35-1.70(m,6H),1.52-1.30(m,1H),0.88-0.75(m,1H),0.46–0.30(m,2H),0.15-0.05(m,2H).

[0145] Example 4: Preparation of Compound 4

[0146] Preparation of compound 4-2

[0147] Compound 4-1 (1.0 g, 4.3 mmol), 1-1 (712 mg, 4.30 mmol), and HATU (2.45 g, 6.45 mmol) were dissolved in DCM (20 mL), and DIPEA (2.22 g, 17.20 mmol) was added. The reaction mixture was stirred at 25°C for 2 hours, concentrated to dryness, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 4-2 (1.3 g, yield 87.8%). LC-MS (ESI): m / z 345.2 [M+H] + .

[0148] Preparation of compound 4-3

[0149] Compound 4-2 (1.38 g, 4.0 mmol) was dissolved in DCM (5 mL) and a 1,4-dioxane solution of hydrochloric acid (4.0 M, 6 mL, 24.0 mmol) was added. The reaction mixture was reacted at room temperature for 3 hours and concentrated to dryness to obtain the crude title compound 4-3, which was used directly in the next step without purification. LC-MS (ESI): m / z 245.2 [M+H] + .

[0150] Preparation of compound 4-4

[0151] Compound 4-3 (1.12 g, 4.0 mmol), compound 1-1a (1.51 g, 6.0 mmol), and HATU (2.28 g, 6.0 mmol) were dissolved in DCM (20 mL). DIPEA (2.07 g, 16.00 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated and dried, and the crude product was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 4-4 (1.90 g, yield 99.48%). LC-MS (ESI): m / z 478.2 [M+H] + .

[0152] Preparation of compound 4-5

[0153] Compound 4-4 (1.91 g, 4.0 mmol) was dissolved in DCM (5 mL) and a 1,4-dioxane hydrochloride solution (4 M, 6.0 mL, 24.0 mmol) was added. The reaction mixture was reacted at room temperature for 3 hours and concentrated to dryness to obtain the crude title compound 4-5, which was used directly in the next step without purification. LC-MS (ESI): m / z 378.2 [M+H] + .

[0154] Preparation of Compound 4-6

[0155] Compound 4-5 (1.66 g, 4.0 mmol) and compound 1-8 (951 mg, 5.0 mmol) were dissolved in DCM (20 mL). HATU (2.26 g, 6.0 mmol) and DIPEA (2.07 g, 16.0 mmol) were added, respectively. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 4-6 (0.88 g, 40.0% yield). LC-MS (ESI): m / z 550.2 [M+H] + .

[0156] Preparation of compound 4

[0157] Compound 4-6 (330 mg, 600 μmol) was dissolved in THF (5 mL). NaOH (192 mg, 4.8 mmol) was added under nitrogen and allowed to react at room temperature for 2 hours. The solution was adjusted to a pH of approximately 4-5 with 1 M dilute hydrochloric acid. The organic solvent was then concentrated and removed. The residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 4 (30 mg, 10.1% yield). LC-MS (ESI): m / z 494.2 [M+H] +; 1 H NMR(400MHz,DMSO-d6)δ12.52(br.s,1H)5.47-5.28(m,1H),4.85-4.77(m,1H),4.71-4.64(m,1H),4.43-4. 30(m,1H),4.10-3.34(m,8H),3.27-2.49(m,4H),2.44-1.89(m,4H),1.76-1.34(m,3H),0.88-0.80(m,6H).

[0158] Example 5: Preparation of Compound 5

[0159] Preparation of compound 5-1

[0160] Compound 1-8 (536.5 mg, 2.82 mmol) was dissolved in DCM (5 mL), and triethylamine (856 mg, 8.46 mmol) and HATU (1.07 g, 2.82 mmol) were added, respectively. The reaction mixture was stirred at room temperature for 1 hour. Compound 2-8 (1.12 g, 2.82 mmol) was then added, and the reaction mixture was stirred at room temperature overnight. Saturated aqueous ammonium chloride (10 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated brine (20 mL × 3), and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and dried. The resulting residue was purified by reverse phase chromatography (C18 column) (mobile phase: ACN / H2O = 0-100%). The collected fractions were concentrated and lyophilized to afford the title compound 5-1 (560 mg, 37.4% yield). LC-MS (ESI): m / z 531.8 [M+H] + .

[0161] Preparation of compound 5

[0162] Compound 5-1 (106.3 mg, 0.20 mmol) was dissolved in THF (0.5 mL), followed by the addition of H₂O (0.5 mL) and sodium hydroxide (32 mg, 0.80 mmol), respectively. The reaction mixture was stirred at room temperature for 1 hour. 2M hydrochloric acid was added to the reaction mixture to adjust the pH to approximately 3. The mixture was filtered through a membrane filter, and the resulting clear solution was subjected to preparative separation and purification (preparative method: mobile phase: A: 0.1% formic acid aqueous solution; B: acetonitrile; column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to afford the title compound 5 (2.8 mg, yield 2.9%). LC-MS (ESI): m / z 476.2 [M+H] + ; 1H NMR (400MHz, Methanol-d4) δ4.58-4.55(m,1H),4.22-4.15(m,1H),3.95-3. 84(m,1H),3.79-3.64(m,3H),3.60-3.50(m,3H),3.41-3.34(m,1H),3.06-2. 95(m,1H),2.80-2.72(s,1H),2.44-2.30(m,1H),2.27-1.90(m,6H),1.86-1 .58(m,3H),1.46-1.39(m,1H),0.83(d,J=6.6Hz,3H),0.79(d,J=6.5Hz,3H).

[0163] Example 6: Preparation of Compound 6

[0164] Preparation of compound 6-2

[0165] Compound 6-1 (200 mg, 1.40 mmol) was dissolved in water (2 mL), and HBr (648 mg, 3.84 mmol, 48% wt) was added. The mixture was cooled to 0°C in an ice-water bath, and a 2 mL aqueous solution of NaNO2 (121 mg, 1.75 mmol) was added dropwise. After addition, the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to remove the organic solvent, yielding the crude title compound 6-2 (145.0 mg, 50% yield). LC-MS (ESI): m / z 206.9 [M+H] + .

[0166] Preparation of compound 6-3

[0167] Compound 6-2 (145.0 mg, 0.7 mmol) was dissolved in DMF (1.5 mL), potassium thioacetate (104 mg, 0.9 mol) was added, and the reaction was stirred at room temperature for 16 h. After the reaction was completed, water was added to dilute the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the title compound 6-3 (136 mg, yield 96%). LC-MS (ESI): m / z 203.0 [M+H] + .

[0168] Preparation of compound 6-4

[0169] Compound 2-8 (221.7 mg, 0.56 mmol) was placed in a three-necked flask, followed by anhydrous DCM (5 mL), compound 6-3 (113.3 mg, 0.56 mmol), HATU (276.8 mg, 0.73 mmol), and DIPEA (361.9 mg, 2.80 mmol). The reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, the solvent was concentrated and an appropriate amount of acetonitrile was added. The product was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 6-4 (100 mg, 32.8% yield). LC-MS (ESI): m / z 544.2 [M+H] + .

[0170] Preparation of compound 6

[0171] Compound 6-4 (100 mg, 0.18 mmol) was dissolved in acetonitrile (1 mL), and aqueous sodium hydroxide (1 M, 2 mL, 2.0 mmol) was added. The reaction mixture was stirred under nitrogen for 2 hours. After the reaction, the pH of the solution was adjusted to approximately 5-6 with dilute hydrochloric acid (1 M). A small amount of deionized water was added, and the reaction solution was filtered through a filter membrane and purified by preparative chromatography (preparative method: mobile phase: A: 0.1% formic acid aqueous solution; B: acetonitrile; column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to obtain the title compound 6 (5.7 mg, 6.5% yield, crude product). The crude compound 6 was purified by SFC preparative purification (preparative conditions: instrument model: Waters 150preparative SFC (SFC-26), chromatographic column model: ChiralPak AD, 250×30mm ID, 5μm, mobile phase: A: CO2, B: isopropanol, elution gradient: B 25%, flow rate: 150mL / min, column pressure: 100bar, column temperature: 38°C, wavelength: 220nm, cycle time: ~3min) to obtain pure compound 6. SFC analysis method (instrument model: Waters UPC2 analytical SFC (SFC-H), chromatographic column model: ChiralPak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (containing 0.05% DEA); elution gradient: mobile phase B increased from 5% to 40% over 4 minutes, then decreased from 40% to 5% over 0.2 minutes and maintained at 5% mobile phase B for the next 1.8 minutes; flow rate: 3.0 mL / min; column temperature: 35°C; column pressure: 100 bar; detection wavelength: 220 nm; RT = 2.825 min); LC-MS (ESI): m / z 488.2 [M+H]+ ; 1 H NMR(400MHz,DMSO-d6)δ12.54(brs,1H),4.84–4.80(m,1H),4.56–4.52(m,1H),4.34–4 .28(m,1H),4.03–3.89(m,2H),3.70–3.56(m,2H),3.51–3.45(m,2H),3.43–3.38(m,1H) ,3.25–3.22(m,1H),3.17–3.12(m,1H),3.01–2.86(m,2H),2.74–2.66(m,1H),2.33–2. 31(m,1H),2.22–2.15(m,2H),2.05–1.87(m,7H),1.81–1.74(m,3H),1.67–1.59(m,2H).

[0172] Example 7: Preparation of Compound 7

[0173] Preparation of compound 7-2

[0174] Compound 7-1 (1.0 g, 6.1 mmol) was dissolved in an aqueous solution of HBr (1.2 mL, 48% wt), cooled to 0°C in an ice-water bath, and an aqueous solution of sodium nitrite (627.3 mg, 9.1 mmol) was slowly added dropwise. The mixture was stirred at this temperature for 3 hours. An aqueous sodium sulfite solution was added to the reaction mixture to quench the reaction. Water (30 mL) was then added, and the mixture was extracted with dichloromethane (50 mL × 2). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude compound 7-2 (1.2 g). LC-MS (ESI): m / z 229.0 [M+H] + .

[0175] Preparation of compound 7-3

[0176] Compound 7-2 (1.2 g, 5.3 mol) was dissolved in acetonitrile (6 mL), and a solution of potassium thioacetate (674.6 mg, 5.9 mol) in water (3 mL) was added. The mixture was allowed to react at room temperature for 3 h. After the reaction, the mixture was filtered, and water (20 mL) was added to the filtrate. The mixture was extracted with dichloromethane (50 mL x 2). The organic phases were combined, washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude title compound 7-3 (1.1 g). LC-MS (ESI): m / z 225.0 [M+H] + .

[0177] Preparation of compound 7-4

[0178] Compound 1-5 (215.9 mg, 0.50 mmol) and compound 7-3 (168.2 mg, 0.75 mmol) were dissolved in DCM (2 mL), and HATU (285.19 mg, 0.75 mmol) and DIPEA (258.49 mg, 2.0 mmol) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 7-4 (100 mg, yield 33.2%). LC-MS (ESI): m / z 602.2 [M+H] + .

[0179] Preparation of compound 7

[0180] Compound 7-4 (100.0 mg, 0.17 mmol) was dissolved in THF (2 mL). Under nitrogen, a 1.0 M aqueous NaOH solution (1.33 mL, 1.33 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. 1 M dilute hydrochloric acid was added to adjust the pH of the solution to approximately 4-5. The organic solvent was then concentrated and removed by evaporation. The residue was purified by preparative chromatography (preparative method: mobile phase: A: 0.1% aqueous formic acid; B: acetonitrile; column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to obtain the title compound 7 (30 mg, yield: 32.3%). LC-MS (ESI): m / z 546.0 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.56(brs,1H),7.30-7.17(m,5H),4.91–4.75(m,2H),4.46–4.15(m,2H),4.02–3.86(m,3H) ,3.73–3.49(m,3H),3.44–3.39(m,1H),3.24–3.13(m,2H),3.03–2.74(m,4H),2.42–2.22(m,2H),2.12–1.89(m,2H).

[0181] Example 8: Preparation of Compound 8

[0182] Preparation of compound 8-2

[0183] Compound 8-1 (300 mg, 1.91 mmol) was dissolved in an aqueous solution of HBr (0.6 mL, 48% wt) and water (2.5 mL). The mixture was cooled to 0°C in an ice-water bath. A solution of sodium nitrite (165 mg, 2.39 mmol) in water (1.5 mL) was slowly added dropwise and stirred at this temperature for 3 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate (50 mL × 3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated to give crude compound 8-2 (269 mg, 64% yield). LC-MS (ESI): m / z 234.9 [M+H] + .

[0184] Preparation of compound 8-3

[0185] Compound 8-2 (269 mg, 1.22 mmol) was dissolved in DMF (3 mL), and KSAc (181 mg, 1.58 mmol) was added. The mixture was allowed to react overnight at room temperature. After completion of the reaction, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude title compound 8-3 (287 mg). LC-MS (ESI): m / z 253 [M+Na] + .

[0186] Preparation of compound 8-4

[0187] Compound 2-8 (257.3 mg, 0.65 mmol) was suspended in DCM (2 mL) and cooled to 0°C in an ice-water bath. Compound 8-3 (301 mg, 1.3 mmol) and HOBT (115 mg, 0.85 mmol) were added, and the reaction mixture was stirred at 0°C for 10 minutes. EDCI (163 mg, 0.85 mmol) was then added, and stirring continued for 10 minutes. DIPEA (380 mg, 2.94 mmol) was then added, and the reaction mixture was brought to room temperature and stirred overnight. Water was added to the reaction mixture, and the mixture was extracted with dichloromethane (50 mL × 3). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. Filtered, concentrated, and dried to dryness, the mixture was pumped dry to afford the crude title compound 8-4 (57 mg, 15% yield). LC-MS (ESI): m / z 572.2 [M+H] + .

[0188] Preparation of compound 8

[0189] Compound 8-4 (57 mg, 0.10 mmol) was dissolved in THF (2 mL). Under nitrogen, aqueous NaOH (1.0 M, 0.5 mL, 0.5 mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours. After the reaction, the reaction solution was directly purified by reverse-phase C18 chromatography (MeCN / H2O (containing 1‰ concentrated hydrochloric acid) = 0-100%) to obtain the title compound 8 (5.7 mg, yield 11.1%). LC-MS (ESI): m / z 516.0 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.59(brs,1H),4.84(t,J=7.2Hz,1H),4.52(m,1H),4.40-4.3 0(m,1H),3.98-3.81(m,2H),3.73-3.66(m,2H),3.63-3.58(m,2H),3.25-3.13(m,2H),3 .01-2.94(m,1H),2.85(d,J=9.6Hz,1H),2.70-2.66(m,1H),2.16-2.03(m,4H),1.94-1. 88(m,4H),1.82-1.66(m,4H),1.42-1.39(m,1H),1.19-1.11(m,4H),0.95-0.78(m,3H).

[0190] Example 9: Preparation of Compound 9

[0191] Preparation of compound 9-1

[0192] Compound 1-5 (172.7 mg, 0.40 mmol) and compound 6-3 (121.4 mg, 0.60 mmol) were dissolved in DCM (2 mL), and HATU (226.4 mg, 0.60 mmol) and DIPEA (206.8 mg, 1.6 mmol) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 9-1 (58 mg, yield 25.0%). LC-MS (ESI): m / z 580.2 [M+H] + .

[0193] Preparation of compound 9

[0194] Compound 9-1 (58.0 mg, 0.10 mmol) was dissolved in THF (1 mL), and aqueous NaOH solution (1.0 M, 0.5 mL, 0.50 mmol) was added under nitrogen protection. The reaction mixture was stirred at room temperature for 2 hours, and 1 M dilute hydrochloric acid was added to adjust the solution to pH 4-5. The organic solvent was concentrated and removed by vortexing. The residue was dissolved in a small amount of acetonitrile and purified by preparative chromatography (preparative method: mobile phase: A: 0.1% formic acid aqueous solution; B: acetonitrile; chromatographic column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to give the title compound 9 (15 mg, yield 28.6%, crude product). The crude compound 9 was purified by SFC preparative purification (preparative conditions: instrument model: MG II preparative SFC (SFC-13), column model: ChiralPak IC, 250×30 mm ID, 10 μm, mobile phase: A: CO2, B: isopropanol, elution gradient: B 25%, flow rate: 80 mL / min, column pressure: 100 bar, column temperature: 38°C, wavelength: 220 nm, cycle time: 1.5 min) to obtain pure compound 9; SFC analysis method (instrument model: Waters UPC2 analytical SFC (SFC-H), column model: ChiralPak IC, 100×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (containing 0.05% DEA); elution gradient: mobile phase B increased from 5% to 40% in 5 minutes, and then maintained in mobile phase B for 2.5 minutes. 40% ratio, and then maintained at 5% mobile phase B for 2.5 minutes; flow rate: 2.5 mL / min; column temperature: 35°C; column pressure: 100 bar; detection wavelength: 220 nm; RT = 3.851 min); LC-MS (ESI): m / z 524.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.62(brs,1H),4.86–4.79(m,2H),4.41–4.27(m,2H),3.98–3.86(m,2H),3.70–3.39(m,5H) ,3.16–3.12(m,1H),3.03–2.86(m,3H),2.34–2.23(m,3H),2.14–1.87(m,5H),1.82–1.73(m,2H),1.67-1.51(m,3H).

[0195] Example 10: Preparation of Compound 10

[0196] Preparation of compound 10-3

[0197] Compound 10-2 (1 g, 5.6 mmol) was suspended in DCM (12 mL), and compound 10-1 (1.2 g, 5.6 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and DIPEA (3.6 g, 27.8 mmol) was added. The mixture was stirred for 10 minutes, and EDCI (1.38 g, 7.24 mmol) was added. Stirring was continued for 10 minutes, followed by the addition of HOBT (978 mg, 7.24 mmol). The reaction mixture was allowed to warm to room temperature and react for 16 hours. After completion of the reaction, water was added, and the mixture was extracted with dichloromethane (100 mL x 3), washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate. The residue was filtered, concentrated, and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 10-3 (1.45 g, 61.0% yield). LC-MS (ESI): m / z 341.2 [M+H] + .

[0198] Preparation of compound 10-4

[0199] Compound 10-3 (1.45 g, 4.26 mmol) was dissolved in DCM (3 mL), and a solution of hydrogen chloride in 1,4-dioxane (4.0 M, 5.0 mL, 20.0 mmol) was added. The mixture was stirred overnight at room temperature. The reaction mixture was concentrated and dried to give the crude title compound 10-4, which was used directly in the next reaction. LC-MS (ESI): m / z 241.2 [M+H] + .

[0200] Preparation of compound 10-5

[0201] Compound 1-1a (547.8 mg, 2.29 mmol), 10-4 (487.1 mg, 1.76 mmol), and HATU (996.0 mg, 2.64 mmol) were dissolved in DCM (5 mL). DIPEA (909.9 mg, 7.04 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction, the reaction mixture was concentrated to dryness, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 10-5 (500.0 mg, 60.0% yield). LC-MS (ESI): m / z 474.2 [M+H] + .

[0202] Preparation of compound 10-6

[0203] Compound 10-5 (834.6 mg, 1.76 mmol) was dissolved in DCM (3 mL) and a solution of hydrogen chloride in 1,4-dioxane (4.0 M, 2.2 mL, 8.80 mmol) was added. The reaction mixture was allowed to react at room temperature for 3 hours. The reaction mixture was concentrated and dried to give the crude title compound 10-6, which was used directly in the next step without purification. LC-MS (ESI): m / z 374.2 [M+H] + .

[0204] Preparation of compound 10-7

[0205] Compound 10-6 (631.2 mg, 1.54 mmol), compound 2-3 (367.1 mg, 1.95 mmol), and HATU (0.877 g, 2.33 mmol) were dissolved in DCM (2 mL). DIPEA (581.6 mg, 4.50 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 10-7 (450 mg, yield 55.2%). LC-MS (ESI): m / z 544.2 [M+H] + .

[0206] Preparation of compound 10

[0207] Compound 10-7 (434.9 mg, 0.80 mmol) was dissolved in THF (3 mL). Under nitrogen, aqueous NaOH (1.0 M, 4.0 mL, 4.0 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction, 1 M hydrochloric acid was added to adjust the solution to a pH of approximately 4-5. The organic solvent was then concentrated and removed. The residue was dissolved in a small amount of acetonitrile, filtered through a filter membrane, and purified by preparative chromatography (preparative method: mobile phase: A: 0.1% formic acid aqueous solution; B: acetonitrile; column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to obtain the title compound 10 (130 mg, 33.3% yield). LC-MS (ESI): m / z 488.3 [M+H] + ; 1H NMR(400MHz,DMSO-d6)δ12.42(brs,1H),5.16–4.79(m,2H),4.56–4.32(m,1H),4.16–3.66(m,5H),3.51–3.44(m,1H),3.18–3.09(m,2H) ,2.97–2.84(m,2H),2.70–2.59(m,1H),2.39–2.07(m,3H),2.03–1.24(m,8H),0.83–0.63(m,1H),0.40–0.30(m,2H),0.11–0.06(m,2H).

[0208] Example 11: Preparation of Compound 11

[0209] Preparation of compound 11-2

[0210] Compound 1-1 (1 g, 6.04 mmol) was suspended in DCM (10 mL), and compound 11-1 (1.4 g, 6.04 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and DIPEA (3.9 g, 30.2 mmol) was added. After stirring for 10 minutes, EDCI (1.5 g, 7.85 mmol) was added. Stirring was continued for 10 minutes, and HOBT (1.06 g, 7.85 mmol) was added. The reaction mixture was brought to room temperature and allowed to react for 16 hours. After completion of the reaction, the reaction mixture was diluted with water, extracted with dichloromethane (100 mL × 3), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 11-2 (1.2 g, 45.0% yield). LC-MS (ESI): m / z 345.2 [M+H] + .

[0211] Preparation of compound 11-3

[0212] Compound 11-2 (1.2 g, 3.48 mmol) was suspended in DCM (3 mL), and a solution of hydrogen chloride in 1,4-dioxane (4.0 M, 4.0 mL, 16.0 mmol) was added. The mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated and dried to give the crude title compound 11-3, which was used directly in the next reaction. LC-MS (ESI): m / z 245.2 [M+H] + .

[0213] Preparation of compound 11-4

[0214] Compound 1-1a (547.8 mg, 2.29 mmol), 11-3 (494.1 mg, 1.76 mmol), and HATU (996.0 mg, 2.64 mmol) were dissolved in DCM (5 mL). DIPEA (909.9 mg, 7.04 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction, the organic solvent was removed by concentration, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 11-4 (500.0 mg, 59.5% yield). LC-MS (ESI): m / z 478.4 [M+H] + .

[0215] Preparation of compound 11-5

[0216] Compound 11-4 (1.91 g, 4.0 mmol) was dissolved in DCM (5 mL), and a solution of hydrogen chloride in 1,4-dioxane (4.0 M, 5.0 mL, 20.0 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated and dried to give the crude title compound 11-5, which was used directly in the next step without purification. LC-MS (ESI): m / z 378.2 [M+H] + .

[0217] Preparation of compound 11-6

[0218] Compound 11-5 (1.66 g, 4.0 mmol), compound 2-3 (941.2 mg, 5.0 mmol), and HATU (1.89 g, 5.0 mmol) were dissolved in DCM (5 mL). DIPEA (1.55 g, 12.0 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 11-6 (1.0 g, yield 45.7%). LC-MS (ESI): m / z 548.2 [M+H] + .

[0219] Preparation of compound 11

[0220] Compound 11-6 (1.1 g, 2.0 mmol) was dissolved in THF (10 mL), and aqueous NaOH solution (1.0 M, 10.0 mL, 10.0 mmol) was added under nitrogen protection, and the reaction mixture was reacted at room temperature for 2 hours. After the reaction, the solution was adjusted to pH 4-5 with 1M dilute hydrochloric acid, and the organic solvent was removed by concentration. The residue was purified by reverse-phase C18 chromatography (MeCN / H2O = 0-100%) to afford crude compound 11 (600 mg). This was then purified by SFC preparative purification (preparative conditions: instrument model: MG II preparative SFC (SFC-13), column model: ChiralPak IC, 250×30 mm ID, 10 μm, mobile phase: A: CO2, B: isopropanol, elution gradient: B 30%, flow rate: 80 mL / min, column pressure: 100 bar, column temperature: 38°C, wavelength: 220 nm, cycle time: ~3 min) to afford the title compound 11 (280 mg). Compound 11: LC-MS (ESI): m / z 492.3 [M+H] + SFC analysis method (instrument model: Waters UPC2 analytical SFC (SFC-H), chromatographic column model: ChiralPak IC-3, 100×4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (0.05% DEA); elution gradient: B from 5% to 40% in 5 minutes, maintaining B at 40% for 2.5 minutes, followed by B at 5% for 2.5 minutes; flow rate: 2.5 mL / min; column temperature: 35°C; column pressure: 100 bar; detection wavelength: 220 nm; RT = 4.383 min); 1 H NMR (400MHz, DMSO-d6) δ5.53–5.20(m,1H),4.98–4.85(m,1H),4.69–4.57(m,1H),4.44–4.27(m,1H),4 .22–4.07(m,1H),4.02–3.84(m,1H),3.80–3.35(m,6H),3.29–3.05(m,1H),3.04–2.94(m,1H),2.93–2 .78(m,1H),2.68–2.51(m,1H),2.38–2.20(m,1H),2.20–2.08(m,1H),2.07–1.97(m,1H),1.96–1.86(m ,1H),1.85–1.73(m,1H),1.43–1.30(m,1H),0.87–0.73(m,1H),0.48–0.29(m,2H),0.17–0.02(m,2H).

[0221] Example 12: Preparation of Compound 12

[0222] Preparation of compound 12-2

[0223] Compound 12-1 (2.05 g, 12.39 mmol) was suspended in anhydrous DCM (15 mL) and cooled to 0°C in an ice-water bath. Compound 1-1a (3.11 g, 12.39 mmol), HATU (6.12 g, 16.10 mmol), and DIPEA (6.40 g, 49.55 mmol) were added sequentially. The reaction mixture was allowed to react at room temperature for 2 hours. After completion of the reaction, the mixture was diluted with DCM (60 mL) and back-extracted with water (20 mL x 2). The organic phase was separated, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and the organic solvent removed. The residue was purified by reverse-phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 12-2 (3.5 g, 78% yield). LC-MS (ESI): m / z 307.0 [M-tBu+H] + ,263.0[M-Boc+H] + .

[0224] Preparation of compound 12-3

[0225] Compound 12-2 (1 g, 2.76 mol) was dissolved in THF (5 mL) and cooled to 0°C in an ice-water bath. An aqueous solution of sodium hydroxide (884 mg, 22.1 mmol) was added, and the reaction mixture was brought to room temperature and stirred for 3 h. After the reaction, the organic solvent was removed by concentration and the solution was adjusted to a pH of approximately 2-3 with 1 M hydrochloric acid. The crude product, compound 12-3 (758 mg), was obtained by lyophilization. LC-MS (ESI): m / z 293.0 [M-tBu+H] + .

[0226] Preparation of compound 12-5

[0227] Compound 12-4 (400 mg, 1.76 mmol) was dissolved in anhydrous DCM (3 mL), cooled to 0°C in an ice-water bath, and a 1,4-dioxane solution of hydrogen chloride (4 M, 3.0 mL, 12.0 mmol) was slowly added dropwise. After addition, the mixture was brought to room temperature and stirred for 2 hours. After the reaction was complete, the mixture was concentrated and dried to give crude compound 12-5 (223 mg). LC-MS (ESI): m / z 128.0 [M+H] + .

[0228] Preparation of compound 12-6

[0229] Compound 12-5 (286.3 mg, 1.75 mol) was dissolved in anhydrous methanol (5 mL) and cooled to 0°C in an ice-water bath. Thionyl chloride (417 mg, 3.5 mol) and 1 drop of anhydrous DMF were added, and the reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, the organic solvent was removed by concentration to obtain crude compound 12-6 (235 mg). LC-MS (ESI): m / z 142.0 [M+H] + .

[0230] Preparation of compound 12-7

[0231] Compound 12-3 (758 mg, 2.18 mmol) was dissolved in anhydrous DCM (10 mL) and cooled to 0°C in an ice-water bath. Compound 12-6 (387.2 mg, 2.18 mmol), HATU (1.24 g, 3.26 mmol), and DIPEA (1.12 g, 8.72 mmol) were added sequentially. The reaction mixture was brought to room temperature and allowed to react for 2 hours. After completion of the reaction, DCM (40 mL) was added for dilution and back-extraction with water (20 mL × 2). The organic phases were combined, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The residue was filtered and concentrated, and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 12-7 (932 mg, 91% yield). LC-MS (ESI): m / z 472.2 [M+H] + .

[0232] Preparation of compound 12-8

[0233] Compound 12-7 (875 mg, 1.86 mol) was dissolved in anhydrous DCM (5 mL) and cooled to 0°C in an ice-water bath. A 4M solution of hydrogen chloride in 1,4-dioxane (4.0 mL, 16.0 mmol) was added and the mixture was allowed to react at room temperature for 2 h. After the reaction, the organic solvent was removed by concentration to obtain crude compound 12-8 (755 mg). LC-MS (ESI): m / z 372.2 [M+H] + .

[0234] Preparation of compound 12-9

[0235] Compound 12-8 (755 mg, 1.85 mmol) was suspended in DCM (10 mL) and cooled to 0°C in an ice-water bath. Compound 2-3 (324 mg, 2.21 mmol), HATU (1.05 g, 2.77 mmol), and DIPEA (0.74 g, 5.74 mmol) were added sequentially. The reaction mixture was brought to room temperature and stirred for 2 hours. After completion of the reaction, DCM (40 mL) was added for dilution and back-extraction with water (20 mL × 2). The organic phase was separated, washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and the organic solvent removed. The residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 12-9 (485 mg, 48.4% yield). LC-MS (ESI): m / z 542.2 [M+H] + .

[0236] Preparation of compound 12

[0237] Compound 12-9 (186 mg, 0.34 mmol) was dissolved in THF (5.0 mL). A solution of sodium hydroxide (105 mg, 2.6 mmol) in water (2 mL) was added at 0°C and allowed to react at room temperature for 2 hours. After completion of the reaction, the organic solvent was concentrated and removed by vortexing. The pH was adjusted to approximately 1-2 with dilute hydrochloric acid. The mixture was filtered through a membrane filter and purified by preparative chromatography (mobile phase: A: 0.1% formic acid in water; B: acetonitrile; column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to obtain the title compound 12 (32 mg, 19.4% yield). LC-MS (ESI): m / z 486.4 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ12.52(brs,1H),4.85-4.79(m,1H),4.55-4.45(m,1H),4.38-4.31(m,1H),4.03-3.81(m,2H),3.79-3.62(m,3H),3.59-3. 44(m,3H),3.01-2.83(m,1H),2.30-1.99(m,3H),1.96-1.55(m,5H),1.4 9-1.31(m,2H),0.87-0.66(m,2H),0.41-0.33(m,2H),0.15-0.03(m,2H).

[0238] Example 13: Preparation of Compound 13

[0239] Preparation of compound 13-1

[0240] Compound 4-5 (362 mg, 0.96 mmol) was suspended in anhydrous DCM (10 mL). Compound 2-3 (202 mg, 1.07 mmol), HATU (528 mg, 1.39 mmol), and DIPEA (495 mg, 3.84 mmol) were added sequentially at 0°C. The reaction mixture was stirred at room temperature for 3 hours. After completion of the reaction, DCM (40 mL) was added for dilution and back-extraction with water (15 mL × 2). The organic phase was separated, washed with saturated brine (10 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 13-1 (246 mg, 46.8% yield). LC-MS (ESI): m / z 548.2 [M+H] + .

[0241] Preparation of compound 13

[0242] Compound 13-1 (246 mg, 0.45 mmol) was dissolved in THF (5.0 mL) and cooled to 0°C in an ice-water bath. A solution of sodium hydroxide (160.0 mg, 4.0 mmol) in water (2 mL) was added and allowed to react at room temperature for 2 hours. After the reaction, the THF was concentrated and removed by vortexing. The pH of the reaction system was adjusted to approximately 1-2 with dilute hydrochloric acid. A small amount of acetonitrile was added to dissolve the product. The product was filtered through a filter membrane and purified by preparative chromatography (preparative method: mobile phase: A: 0.1% formic acid in water; B: acetonitrile; column: Welch Ultimate AQ-C18 250×21.2 mm; column temperature: 25°C; flow rate: 30 mL / min) to obtain the title compound 13 (56 mg, yield: 25.3%). LC-MS (ESI): m / z 492.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.36(brs,1H),5.47-5.22(m,1H),4.85-4.60(m,2H ),4.50-4.32(m,1H),4.29-4.18(m,1H),4.14-3.88(m,2H),3.83-3.48(m,4H) ,3.06-2.54(m,3H),2.40-2.25(m,1H),2.19-2.05(m,2H),1.98-1.71(m,4H) ,1.48-1.24(m,1H),0.84-0.63(m,1H),0.43-0.30(m,2H),0.14-0.05(m,2H).

[0243] Example 14: Preparation of Compound 14

[0244] Preparation of compound 14-2

[0245] Compound 14-1 (100 mg, 0.64 mmol) and hydrobromic acid (61.8 mg, 0.76 mmol, 48 wt%) were dissolved in H₂O (1.5 mL). A solution of NaNO₂ (52.7 mg, 0.76 mmol) in water (1.5 mL) was slowly added dropwise at 0°C. After complete addition, the mixture was allowed to react at room temperature for 3 hours. After completion of the reaction, the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated to remove the organic solvent to obtain the crude title compound 14-2 (110 mg). LC-MS (ESI): m / z 221.0 [M+H] + .

[0246] Preparation of compound 14-3

[0247] Compound 14-2 (500 mg, 2.26 mmol) and potassium thioacetate (387.4 mg, 3.39 mmol) were added to DMF (3 mL), and the reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the mixture was diluted with water and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and the organic solvent was removed to obtain the crude title compound 14-3 (424 mg). LC-MS (ESI): m / z 217.2 [M+H] + .

[0248] Preparation of compound 14-4

[0249] Compound 2-8 (277 mg, 0.70 mmol) was suspended in DCM (2 mL), and compound 14-3 (150.5 mg, 0.70 mmol) and HATU (317.2 mg, 0.83 mmol) were added sequentially. The mixture was cooled to 0°C in an ice-water bath, and DIPEA (450 mg, 3.48 mmol) was added. The reaction mixture was brought to room temperature and stirred for 16 hours. After completion of the reaction, the reaction mixture was diluted with water, extracted with dichloromethane (20 mL × 3), washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The residue was filtered and concentrated, and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 14-4 (225 mg, 57.6% yield). LC-MS (ESI): m / z 558.2 [M+H] + .

[0250] Preparation of compound 14

[0251] Compound 14-4 (225 mg, 0.40 mmol) was placed in a three-necked flask, followed by anhydrous THF (2 mL). The reaction system was purged with nitrogen three times, and then an aqueous NaOH solution (2 mL, 2.0 mmol, 1.0 M) was added at 0°C. The reaction system was stirred at room temperature for 2 hours. After the reaction, the pH of the solution was adjusted to approximately 2-3 with dilute hydrochloric acid, concentrated, and a small amount of acetonitrile was added to the residue. The title compound 14 (114 mg, 57.5% yield) was obtained by purification via a reverse-phase C18 column (MeCN / H2O = 0-100%). LC-MS (ESI): m / z 502.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ12.53(brs,1H),4.85–4.81(m,1H),4.56–4.50(m,1H),4.38–4.27(m,1H),4.00–3.82(m,1H),3.71–3. 58(m,3H),3.54–3.45(m,4H),3.02–2.90(m,2H),2.19–2.02(m,3H),1.94–1.68(m,7H),1.55–1.41(m,6H),1.15–0.97(m,3H).

[0252] Example 15: Preparation of Compound 15

[0253] Preparation of compound 15-2

[0254] Compound 15-1 (300 mg, 2.1 mmol) and hydrobromic acid (423.8 mg, 2.51 mmol, 48 wt%) were dissolved in H₂O (3 mL). A solution of NaNO₂ (173.5 mg, 0.76 mmol) in water (3 mL) was slowly added dropwise at 0°C. After complete addition, the mixture was allowed to react at room temperature for 3 hours. After completion of the reaction, the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and the organic solvent removed to obtain the crude title compound 15-2 (357 mg). LC-MS (ESI): m / z 207.0 [M+H] + .

[0255] Preparation of compound 15-3

[0256] Compound 15-2 (247 mg, 1.19 mmol) and potassium thioacetate (204.4 mg, 1.79 mmol) were added to DMF (3 mL), and the reaction mixture was stirred at room temperature overnight. After completion of the reaction, the mixture was diluted with water and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, concentrated, and the organic solvent was removed to obtain the crude title compound 15-3 (185 mg). LC-MS (ESI): m / z 203.2 [M+H] + .

[0257] Preparation of compound 15-4

[0258] Compound 2-8 (277 mg, 0.70 mmol) was suspended in DCM (2 mL), and compound 15-3 (140.7 mg, 0.70 mmol) and HATU (317.2 mg, 0.83 mmol) were added sequentially. The mixture was cooled to 0°C in an ice-water bath, and DIPEA (450 mg, 3.48 mmol) was added. The reaction mixture was brought to room temperature and stirred for 4 hours. After the reaction was completed, the reaction mixture was diluted with water, extracted with dichloromethane (20 mL × 3), washed with saturated brine (20 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 15-4 (95 mg, yield 25.1%). LC-MS (ESI): m / z 544.2 [M+H] + .

[0259] Preparation of compound 15

[0260] Compound 15-4 (95 mg, 0.17 mmol) was placed in a three-necked flask, followed by anhydrous THF (2 mL). The reaction system was purged with nitrogen three times, and then an aqueous NaOH solution (2 mL, 2.0 mmol, 1.0 M) was added at 0°C. The reaction system was stirred at room temperature for 3 hours. After the reaction, the pH of the solution was adjusted to approximately 2-3 with dilute hydrochloric acid, concentrated, and the residue was dissolved in a small amount of acetonitrile and directly purified by reverse-phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 15 (24 mg, yield 29.0%). LC-MS (ESI): m / z 488.2 [M+H] + ; 1H NMR(400MHz, DMSO-d6)δ12.50(brs,1H),4.84(dd,J=9.1,6.2Hz,1H),4.54(dd,J=8.5,4.0H z,1H),4.33–4.25(m,1H),3.96–3.85(m,1H),3.72–3.66(m,2H),3.64–3.56(m,2H),3.54–3. 47(m,2H),3.44–3.39(m,2H),3.19–3.11(m,1H),3.04–2.89(m,2H),2.35–2.02(m,4H),1.9 6–1.87(m,3H),1.79–1.58(m,2H),1.32–1.08(m,3H),0.70–0.60(m,1H),0.40–0.37(m,2H).

[0261] Example 16: Preparation of Compound 16

[0262] Preparation of compound 16-1

[0263] Compound 2-8 (775.8 mg, 1.96 mmol) was suspended in DCM (10 mL), and compound 7-3 (878 mg, 3.92 mmol) and HATU (1.17 g, 2.94 mmol) were added sequentially. The mixture was cooled to 0°C in an ice-water bath, and DIPEA (1.14 g, 8.82 mmol) was added. The reaction mixture was brought to room temperature and stirred for 2 hours. After the reaction was completed, the reaction mixture was diluted with water, extracted with dichloromethane (100 mL × 3), washed with saturated brine (50 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 16-1 (179 mg, yield 16.1%). LC-MS (ESI): m / z 566.2 [M+H] + .

[0264] Preparation of compound 16

[0265] Compound 16-1 (179 mg, 0.32 mmol) was placed in a three-necked flask, followed by anhydrous THF (1 mL). The reaction system was purged with nitrogen three times. Aqueous NaOH (1 mL, 1.0 mmol, 1.0 M) was added at 0°C, and the reaction system was stirred at room temperature for 1.5 hours. After the reaction, the solution was adjusted to a pH of approximately 2-3 with dilute hydrochloric acid and concentrated. The residue was dissolved in a small amount of acetonitrile and directly purified by reverse-phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 16 (52 mg, yield 31.9%). LC-MS (ESI): m / z 510.2 [M+H]+ ; 1 H NMR(400MHz,DMSO-d6)δ12.43(brs,1H),7.22–7.13(m,5H),4.82–4.66(m,1H),4. 49–4.42(m,1H),4.31–4.07(m,1H),3.98–3.76(m,2H),3.69–3.56(m,2H),3.51–3. 40(m,3H),3.36–3.31(m,2H),3.13–3.05(m,2H),2.96–2.75(m,2H),2.27–2.25(m ,1H),2.15–2.04(m,2H),1.89–1.81(m,2H),1.71–1.61(m,1H),1.19–1.14(m,1H).

[0266] Example 17: Preparation of Compound 17

[0267] Preparation of compound 17-2

[0268] Compound 17-1 (2.0 g, 8.2 mmol) was dissolved in DCM (10 mL). A solution of hydrogen chloride in 1,4-dioxane (10 mL, 40.0 mmol, 4.0 M) was added, and the reaction mixture was stirred at room temperature for 1.5 hours. After the reaction, the organic solvent was removed by concentration to obtain crude compound 17-2, which was used directly in the next reaction. LC-MS (ESI): m / z 144.2 [M+H] + .

[0269] Preparation of compound 17-3

[0270] Compound 17-2 (1.47 g, 8.2 mmol) was suspended in DCM (20 mL), and compound 10-1 (1.77 g, 8.2 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and HATU (4.7 g, 12.3 mmol) was added. Stirring was continued for 5 minutes, followed by the addition of DIPEA (4.8 g, 37.0 mmol). The reaction mixture was brought to room temperature and allowed to react for 2 hours. After completion of the reaction, the mixture was diluted with water and extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 17-3 (1.87 g, 67.0% yield). LC-MS (ESI): m / z 341.4 [M+H] + .

[0271] Preparation of compound 17-4

[0272] Compound 17-3 (1.77 g, 5.2 mmol) was dissolved in DCM (10 mL), and a solution of hydrogen chloride in 1,4-dioxane (7 mL, 28.0 mmol, 4.0 M) was added. The reaction mixture was stirred at room temperature for 1.5 hours. After the reaction, the organic solvent was removed by concentration to obtain crude compound 17-4, which was used directly in the next reaction. LC-MS (ESI): m / z 241.2 [M+H] + .

[0273] Preparation of compound 17-5

[0274] Compound 17-4 (1.44 g, 5.2 mmol) was suspended in DCM (20 mL), and compound 1-1a (1.31 g, 5.2 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and HATU (2.97 g, 7.8 mmol) was added. Stirring was continued for 5 minutes, and DIPEA (3.02 g, 23.4 mmol) was added. The reaction mixture was brought to room temperature and reacted for 2 hours. After completion of the reaction, the mixture was diluted with water and extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 17-5 (1.87 g, yield 76.0%). LC-MS (ESI): m / z 474.3 [M+H] + .

[0275] Preparation of compound 17-6

[0276] Compound 17-5 (1 g, 2.1 mmol) was dissolved in DCM (5 mL), and a solution of hydrogen chloride in 1,4-dioxane (3 mL, 12.0 mmol, 4.0 M) was added. The reaction mixture was stirred at room temperature for 1.5 hours. After the reaction, the organic solvent was removed by concentration to obtain crude compound 17-6, which was used directly in the next reaction. LC-MS (ESI): m / z 374.2 [M+H] + .

[0277] Preparation of compound 17-7

[0278] Compound 17-6 (1.72 g, 4.2 mmol) was suspended in DCM (10 mL), and compound 2-3 (1.58 g, 8.4 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and HATU (2.38 g, 6.25 mmol) was added. After stirring for 5 minutes, DIPEA (2.44 g, 18.90 mmol) was added, and the reaction mixture was brought to room temperature and reacted for 2 hours. After the reaction was completed, the mixture was diluted with water and extracted with dichloromethane. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The residue was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 17-7 (1.2 g, yield 52.6%). LC-MS (ESI): m / z 544.4 [M+H] + .

[0279] Preparation of compound 17

[0280] Compound 17-7 (200 mg, 0.18 mmol) was placed in a three-necked flask, followed by anhydrous THF (3 mL). The reaction system was purged with nitrogen three times. Aqueous NaOH (1.84 mL, 1.84 mmol, 1.0 M) was added at 0°C, and the reaction system was stirred at room temperature for 2 hours. After the reaction, the solution was adjusted to a pH of approximately 2-3 with 2M hydrochloric acid and concentrated. The residue was dissolved in a small amount of acetonitrile and directly purified by reverse-phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 17 (46 mg, yield 25.6%). LC-MS (ESI): m / z 488.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.60(brs,1H),4.90–4.78(m,1H),4.61–4.45(m,1H ),4.40–4.32(m,1H),3.76–3.59(m,4H),3.56–3.47(m,2H),3.03–2.83(m,2H) ,2.37–2.23(m,2H),2.22–2.11(m,2H),1.97–1.88(m,2H),1.86–1.63(m,4H) ,1.29–1.19(m,4H),0.87–0.69(m,1H),0.46–0.30(m,2H),0.17–0.01(m,2H).

[0281] Example 18: Preparation of Compound 18

[0282] Preparation of compound 18-2

[0283] Compound 18-1 (1.0 g, 4.1 mmol) was dissolved in DCM (20 mL), and a solution of hydrogen chloride in 1,4-dioxane (9 mL, 36.0 mmol, 4.0 M) was added. The reaction mixture was stirred at room temperature for 1.5 hours. After the reaction, the organic solvent was removed by concentration to obtain crude compound 18-2, which was used directly in the next reaction. LC-MS (ESI): m / z 146.2 [M+H] + .

[0284] Preparation of compound 18-3

[0285] Compound 18-2 (744.6 mg, 4.1 mmol) was suspended in DCM (8 mL), and compound 10-1 (870 mg, 4.1 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and HATU (2.3 g, 6.12 mmol) was added. Stirring was continued for 5 minutes, followed by the addition of DIPEA (2.37 g, 18.3 mmol). The reaction mixture was brought to room temperature and allowed to react for 2 hours. After completion of the reaction, the mixture was diluted with water and extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 18-3 (900 mg, 64.1% yield). LC-MS (ESI): m / z 343.2 [M+H] + .

[0286] Preparation of compound 18-4

[0287] Compound 18-3 (900 mg, 3.7 mmol) was dissolved in DCM (3 mL) and a solution of hydrogen chloride in 1,4-dioxane (5 mL, 20.0 mmol, 4.0 M) was added. The reaction mixture was stirred at room temperature for 1.5 hours. After the reaction, the organic solvent was removed by concentration to obtain crude compound 18-4, which was used directly in the next reaction. LC-MS (ESI): m / z 243.2 [M+H] + .

[0288] Preparation of compound 18-5

[0289] Compound 18-4 (1.03 g, 3.7 mmol) was suspended in DCM (7 mL), and compound 1-1a (929.6 mg, 3.7 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and HATU (2.1 g, 5.5 mmol) was added. Stirring was continued for 5 minutes, followed by the addition of DIPEA (2.1 g, 16.6 mmol). The reaction mixture was brought to room temperature and allowed to react for 2 hours. After completion of the reaction, the mixture was diluted with water and extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 18-5 (870 mg, 49.5% yield). LC-MS (ESI): m / z 476.3 [M+H] + .

[0290] Preparation of compound 18-6

[0291] Compound 18-5 (870 mg, 1.8 mmol) was dissolved in DCM (7 mL), and a solution of hydrogen chloride in 1,4-dioxane (3 mL, 12.0 mmol, 4.0 M) was added. The reaction mixture was stirred at room temperature for 1.5 hours. After the reaction, the organic solvent was removed by concentration to obtain crude compound 18-6, which was used directly in the next reaction. LC-MS (ESI): m / z 376.2 [M+H] + .

[0292] Preparation of compound 18-7

[0293] Compound 18-6 (0.74 g, 1.8 mmol) was suspended in DCM (10 mL), and compound 2-3 (0.69 g, 3.6 mmol) was added. The mixture was cooled to 0°C in an ice-water bath, and HATU (1.06 g, 2.7 mmol) was added. Stirring was continued for 5 minutes, followed by the addition of DIPEA (1.06 g, 8.3 mmol). The reaction mixture was brought to room temperature and allowed to react for 2 hours. After completion of the reaction, the mixture was diluted with water and extracted with dichloromethane. The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The residue was filtered and concentrated, and purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 18-7 (530 mg, 54.0% yield). LC-MS (ESI): m / z 546.2 [M+H] + .

[0294] Preparation of compound 18

[0295] Compound 18-7 (202 mg, 0.37 mmol) was placed in a three-necked flask, followed by anhydrous THF (3 mL). The reaction system was purged with nitrogen three times. Aqueous NaOH (2.0 mL, 2.0 mmol, 1.0 M) was added at 0°C, and the reaction system was stirred at room temperature for 2 hours. After the reaction, the solution was adjusted to a pH of approximately 2-3 with 2M hydrochloric acid and concentrated. The residue was dissolved in a small amount of acetonitrile and directly purified by reverse-phase C18 chromatography (MeCN / H2O = 0-100%) to obtain the title compound 18 (70 mg, yield 38.6%). LC-MS (ESI): m / z 490.2 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.67(brs,1H),4.84(m,1H),4.61–4.46(m,1H),4. 40–4.33(m,1H),4.04–3.82(m,2H),3.76–3.63(m,3H),3.59–3.49(m,4H),3 .00–2.93(m,1H),2.29–2.07(m,3H),2.00–1.92(m,3H),1.84–1.72(m,2H), 1.48–1.24(m,2H),0.86–0.73(m,1H),0.38–0.34(m,2H),0.11–0.08(m,2H).

[0296] Example 19: Preparation of Compound 19

[0297] Preparation of compound 19-2

[0298] Compound 19-1 (1.0 g, 6.36 mmol) was dissolved in a mixed solution of water (6 mL) and hydrobromic acid (5.36 g, 31.80 mmol, 48% wt). The mixture was cooled to 0°C in an ice-water bath and stirred at this temperature for 30 minutes. A solution of NaNO2 (702.2 mg, 10.18 mmol) in water (3 mL) was slowly added dropwise. After the addition, the mixture was stirred at 0°C for 2 hours. The ice-water bath was removed, and the mixture was gradually warmed to room temperature and stirred for another 2 hours. Water (50 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The organic phases were combined, washed with saturated brine (100 mL × 3), and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated to obtain the crude title compound 19-2 (0.8 g, 56.7% yield). LC-MS (ESI): m / z 220.9 [M+H] + .

[0299] Preparation of compound 19-3

[0300] Compound 19-2 (0.8 g, 3.62 mol) was dissolved in acetonitrile (6 mL) and water (3 mL). Potassium thioacetate (620.1 mg, 5.43 mmol) was added and allowed to react at room temperature for 2 h. After completion of the reaction, water (5 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (50 mL × 3). The organic phase was washed with saturated aqueous ammonium chloride (100 mL × 3) and dried over anhydrous sodium sulfate. Filtering and concentration afforded the crude title compound 19-3 (0.6 g, 76.6% yield).

[0301] Preparation of compound 19-4

[0302] Compound 19-3 (413.7 mg, 1.91 mmol), compound 2-8 (593.7 mg, 1.5 mmol), and HATU (760.5 mg, 2.0 mmol) were dissolved in DCM (5 mL), and DIPEA (581.6 mg, 4.50 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness, and the residue was purified by reverse phase C18 chromatography (MeCN / H2O = 0-100%) to give the title compound 19-4 (450 mg, 53.8% yield). LC-MS (ESI): m / z 558.2 [M+H] + .

[0303] Preparation of compound 19

[0304] Compound 19-4 (446.1 mg, 0.80 mmol) was dissolved in THF (3 mL). Under nitrogen, a 1.0 M aqueous NaOH solution (3.2 mL, 3.2 mmol) was added and allowed to react at room temperature for 2 hours. After completion of the reaction, the solution was adjusted to a pH of approximately 4-5 with 1 M hydrochloric acid. The organic solvent was then concentrated and removed. The residue was purified by reverse-phase C18 chromatography (MeCN / H2O = 0-100%) to afford the title compound 19 (10 mg, 19.9% ​​yield). LC-MS (ESI): m / z 502.4 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.51(brs,1H),5.14–4.81(m,1H),4.67–4.48(m,1H),4.39–4.23(m,1H) ,4.00–3.37(m,9H),3.20–2.88(m,3H),2.33–1.88(m,8H),1.84–1.63(m,4H),1.58–1.25(m,5H).

[0305] Test Example 1: Testing of Compounds in Recombinant Human APP2 Enzyme (hAPP2)

[0306] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0307] Prepare the test compound solution: Prepare the test compound to a concentration of 40 μM in the test buffer; set up 10 concentration gradients and dilute the above compound three times with the test buffer supplemented with 1.3% DMSO. The final working concentrations of the compound are 10 μM, 3.33 μM, 1.11 μM, 0.37 μM, 0.12 μM, 0.041 μM, 0.014 μM, 0.0045 μM, 0.0015 μM, 0.0005 μM; alternatively, the final working concentrations of the compound are 1 μM, 0.33 μM, 0.11 μM, 0.037 μM, 0.012 μM, 0.004 μM, 0.0014μM, 0.00046μM, 0.00015μM, 0.00005μM; alternatively, the final working concentrations of the compounds are 0.1μM, 0.033μM, 0.011μM, 0.0037μM, 0.0012μM, 0.0004μM, 0.00014μM, 0.000046μM, 0.000015μM, 0.000005μM, respectively.

[0308] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 1.3% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0309] 2. Prepare a recombinant human APP2 enzyme solution in assay buffer at a concentration of 1 nM. Add 5 μL of recombinant human APP2 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0310] 3. Prepare a 20 μM Lys(Abz)-Pro-Pro-pNA substrate solution in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 30°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0311] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0312] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0313] Test Example 2: Testing of Compounds in Recombinant Mouse APP2 Enzyme (mAPP2)

[0314] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0315] Prepare the test compound solution: Prepare the test compound to a concentration of 40 μM in the test buffer; set up 10 concentration gradients and dilute the above compound three times with the test buffer supplemented with 1.3% DMSO. The final working concentrations of the compound are 10 μM, 3.33 μM, 1.11 μM, 0.37 μM, 0.12 μM, 0.041 μM, 0.014 μM, 0.0045 μM, 0.0015 μM, 0.0005 μM; alternatively, the final working concentrations of the compound are 1 μM, 0.33 μM, 0.11 μM, 0.037 μM, 0.012 μM, 0.004 μM, 0.0014μM, 0.00046μM, 0.00015μM, 0.00005μM; alternatively, the final working concentrations of the compounds are 0.1μM, 0.033μM, 0.011μM, 0.0037μM, 0.0012μM, 0.0004μM, 0.00014μM, 0.000046μM, 0.000015μM, 0.000005μM, respectively.

[0316] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 1.3% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0317] 2. Prepare a 2 nM recombinant mouse APP2 enzyme solution in assay buffer. Add 5 μL of recombinant mouse APP2 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 min.

[0318] 3. Prepare a 6 μM solution of the substrate Lys(Abz)-Pro-Pro-pNA in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 30°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0319] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0320] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0321] Testing of compounds in recombinant rat APP2 enzyme (rAPP2)

[0322] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0323] Prepare the test compound solution: Prepare the test compound to a concentration of 40 μM in the test buffer; set up 10 concentration gradients and dilute the above compound three times with the test buffer supplemented with 1.3% DMSO. The final working concentrations of the compound are 10 μM, 3.33 μM, 1.11 μM, 0.37 μM, 0.12 μM, 0.041 μM, 0.014 μM, 0.0045 μM, 0.0015 μM, 0.0005 μM; alternatively, the final working concentrations of the compound are 1 μM, 0.33 μM, 0.11 μM, 0.037 μM, 0.012 μM, 0.004 μM, 0.0014μM, 0.00046μM, 0.00015μM, 0.00005μM; alternatively, the final working concentrations of the compounds are 0.1μM, 0.033μM, 0.011μM, 0.0037μM, 0.0012μM, 0.0004μM, 0.00014μM, 0.000046μM, 0.000015μM, 0.000005μM, respectively.

[0324] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 1.3% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0325] 2. Prepare a 1 nM recombinant rat APP2 enzyme solution in assay buffer. Add 5 μL of recombinant rat APP2 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0326] 3. Prepare a 20 μM Lys(Abz)-Pro-Pro-pNA substrate solution in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 30°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0327] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0328] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0329] Test Example 3: Testing of Compounds in Recombinant Human ACE1 Enzyme (hACE1)

[0330] 1. Prepare assay buffer: 50 mM HEPES, 50 mM NaCl, 3 μM ZnCl2, 0.002% BSA, 0.005% Triton-100, pH 7.5, freshly prepared for use.

[0331] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0332] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0333] 2. Prepare recombinant human ACE1 enzyme solution in assay buffer at a concentration of 0.4 nM. Add 5 μL of recombinant human ACE1 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0334] 3. Prepare a 4 μM solution of the substrate MCA-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(DNP)-OH in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0335] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0336] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0337] Test Example 4: Testing of Compounds in Recombinant Human ACE2 (hACE2) Enzyme

[0338] 1. Prepare assay buffer: 50 mM HEPES, 150 mM NaCl, 0.002% BSA, 0.0025% Tween 20, pH 7.5, freshly prepared. Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by diluting the compound three-fold in assay buffer supplemented with 2% DMSO. Final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0339] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0340] 2. Prepare a 16 nM recombinant human ACE2 enzyme solution in assay buffer. Add 5 μL of recombinant human ACE2 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0341] 3. Prepare a 70 μM solution of the substrate Mca-Tyr-Val-Ala-Asp-Ala-Pro-Lys(Dnp)-OH in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0342] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0343] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0344] Test Example 5: Testing of Compounds in Recombinant Human APN Enzyme (hAPN)

[0345] 1. Prepare assay buffer: 50 mM HEPES, 0.00125% Tween 20, pH 7.0, freshly prepared for use.

[0346] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0347] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0348] 2. Prepare a 4 nM recombinant human APN enzyme solution in assay buffer. Add 5 μL of recombinant human APN enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0349] 3. Prepare a 200 μM substrate solution of Ala-AMC in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate on a Molecular Devices SpectraMax microplate reader at 25°C, with excitation at 380 nm and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0350] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0351] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0352] Test Example 6: Testing of Compounds in Recombinant Human APP1 Enzyme (hAPP1)

[0353] 1. Prepare assay buffer: 50 mM HEPES, 150 mM NaCl, 0.002% BSA, 0.0025% Tween 20, pH 7.5, freshly prepared. Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by diluting the compound three-fold in assay buffer supplemented with 2% DMSO. Final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0354] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0355] 2. Prepare a 12 nM recombinant human APP1 enzyme solution in assay buffer. Add 5 μL of recombinant human APP1 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0356] 3. Prepare a 50 μM Lys(ABZ)Pro-Pro-PNA substrate solution in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0357] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0358] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0359] Test Example 7: Testing of Compounds in Recombinant Human DPP4 Enzyme (hDPP4)

[0360] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0361] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by diluting the compound three-fold in assay buffer supplemented with 0.66% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0362] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 0.66% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0363] 2. Prepare recombinant human DPP4 enzyme solution in assay buffer at a concentration of 8 nM. Add 5 μL of recombinant human DPP4 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0364] 3. Prepare a 540 μM substrate solution of Gly-Pro-pNA (hydrochloride) in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C and absorbance at 405 nm, reading every 2 minutes for 30 minutes.

[0365] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0366] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0367] Test Example 8: Testing of Compounds in Recombinant Human ECE1 Enzyme (hECE1)

[0368] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0369] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0370] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0371] 2. Prepare recombinant human ECE1 enzyme solution in assay buffer at a concentration of 4 nM. Add 5 μL of recombinant human ECE1 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 min.

[0372] 3. Prepare a 20 μM solution of the substrate MCA-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(DNP)-OH in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0373] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0374] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0375] Test Example 9: Testing of Compounds in Recombinant Human ENPEP Enzyme (hENPEP)

[0376] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0377] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0378] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0379] 2. Prepare a 5 nM recombinant human ENPEP enzyme solution in assay buffer. Add 5 μL of recombinant human ENPEP enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 min.

[0380] 3. Prepare a substrate solution of L-glutamic acid-α-7-amido-4-methylcoumarin in assay buffer at a concentration of 80 μM. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0381] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0382] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0383] Test Example 10: Testing of Compounds in Recombinant Human RNPEP Enzyme (hRNPEP)

[0384] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0385] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0386] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0387] 2. Prepare a 20 nM recombinant human RNPEP enzyme solution in assay buffer. Add 5 μL of recombinant human RNPEP enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0388] 3. Prepare a 40 μM solution of the substrate, L-Arg-7-amido-4-methylcoumarin-HCl, in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0389] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0390] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0391] Test Example 11: Testing of Compounds in Recombinant Human ERAP2 Enzyme (hERAP2)

[0392] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0393] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0394] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0395] 2. Prepare recombinant human ERAP2 enzyme solution in assay buffer at a concentration of 16 nM. Add 5 μL of recombinant human ERAP2 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0396] 3. Prepare the substrate L-Arg-7-amido-4-methylcoumarin-HCl solution in assay buffer at a concentration of 8 μM. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0397] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0398] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0399] Test Example 12: Testing of Compounds in Recombinant Human Neprilysin Enzyme (hNeprilysin)

[0400] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0401] Prepare test compound solutions: Prepare test compound solutions at a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by diluting the compound three-fold in assay buffer supplemented with 2% DMSO. Final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0402] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0403] 2. Prepare recombinant human neprilysin enzyme solution in assay buffer at a concentration of 2 nM. Add 5 μL of recombinant human neprilysin enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0404] 3. Prepare a 10 μM solution of the substrate MCA-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(DNP)-OH in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0405] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0406] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0407] Test Example 13: Testing of Compounds in Recombinant Human Neurolysin Enzyme (hNeurolysin)

[0408] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0409] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0410] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0411] 2. Prepare a 2 nM recombinant human Neurolysin enzyme solution in assay buffer. Add 5 μL of recombinant human Neurolysin enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 minutes.

[0412] 3. Prepare a 20 μM solution of the substrate MCA-Pro-Leu-Gly-Pro-D-Lys(DNP)-OH in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0413] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0414] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0415] Test Example 14: Testing of Compounds in Recombinant Human THOP1 Enzyme (hTHOP1)

[0416] 1. Prepare assay buffer: 50 mM HEPES, 0.002% BSA, pH 7.5, freshly prepared for use.

[0417] Prepare test compound solutions: Prepare the test compound to a concentration of 200 μM in assay buffer. Set up a 10-step concentration gradient by three-fold dilution of the compound in assay buffer supplemented with 2% DMSO. The final working concentrations are 50 μM, 16.67 μM, 5.56 μM, 1.85 μM, 0.617 μM, 0.206 μM, 0.069 μM, 0.023 μM, 0.008 μM, and 0.003 μM.

[0418] Min / Max wells were set on a 384-well plate. 5 μL of assay buffer containing 2% DMSO was added to each of the Min / Max wells, and 5 μL of the test compound solution prepared above was added to each of the remaining wells.

[0419] 2. Prepare recombinant human THOP1 enzyme solution in assay buffer at a concentration of 4 nM. Add 5 μL of recombinant human THOP1 enzyme solution to the Max well and compound wells, and 5 μL of assay buffer to the Min wells. Centrifuge and incubate at room temperature for 30 min.

[0420] 3. Prepare a 60 μM solution of the substrate MCA-Pro-Leu-Gly-Pro-D-Lys(DNP)-OH in assay buffer. After incubation, add 10 μL of substrate solution to each well. After centrifugation, immediately read the plate using a PerkinElmer Envision microplate reader at 25°C, excitation at 340 nm, and emission at 460 nm. Read every 2 minutes for 30 minutes.

[0421] 4. Using Excel, insert the function SLOPE, Known_y's = Relative Fluorescence Unit (RFU), Known_x's = Time (min) to calculate the initial velocity of the enzymatic reaction. Calculate the inhibition rate of the compound on the enzyme using the following formula: Inhibition rate % = [(Max initial velocity of the well - initial velocity of the compound well) / (Max initial velocity of the well - minimum initial velocity of the well)] × 100%

[0422] 5. Using Graphpad Prism 8, set the X-axis to compound (μM) and the Y-axis to Inhibition %, and use the formula XY analyses / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibitor) vs. response-Variable slope (four parameters) to perform curve fitting and calculate the IC 50 value.

[0423] Table 1: Activity test results of compounds in some recombinant enzymes IC 50 (μM)

[0424] Table 2: Activity test results of compounds in some recombinant enzymes IC 50 (μM)

[0425] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0426] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A compound represented by formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, in, R1 is selected from C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted with 1, 2 or 3 R; R2 is selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted with 1, 2 or 3 R; R3 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R; R4 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R; R5 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R; R6 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R; R7 is selected from H, F, Cl, Br, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R; Alternatively, R6 and R7 are connected together to form a C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 R; R8 is selected from H or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R; Alternatively, R6 and R8 are connected together to form a bridge ring; R9 is selected from H, halogen or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R; R 10 Selected from H, halogen, OH, CN, NH2 or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R; Or, R9 and R 10 Connect together to form a C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 R; R 11 Select from H, D or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 R; Or, R1 and R 11 Connect together to form a C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl, the C 3-6 Cycloalkyl and 3-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R; R 12 Selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 6-10 Aryl and 5-10 membered heteroaryl are optionally substituted with 1, 2 or 3 R; L1 is selected from a single bond or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R; L2 is selected from a single bond or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R; L3 is selected from a single bond or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R; L4 is selected from a single bond, -O- or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R; L5 is selected from a single bond, -C(=O)-, -C(=O)-(CH2) n -or-(CH2) n -, said -C(=O)-(CH2) n - and -(CH2) n -optionally substituted with 1 or 2 R; L6 is selected from a single bond or -(CH2) n -, the -(CH2) n -optionally substituted with 1 or 2 R; n is independently selected from 0, 1, 2, 3, 4, 5 or 6; R is independently selected from H, F, Cl, Br, OH, NH2, CN, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio and C 1-6 Alkylamino, the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The alkylamino group is optionally substituted with 1, 2 or 3 R'; R' is selected from F, Cl, Br, I, OH, NH2 and CH3; C 1-6 The heteroalkyl or 5-10 membered heteroaryl group contains 1, 2 or 3 heteroatoms or heteroatom groups independently selected from -O-, -NH-, -S-, -C(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2- and N.

2. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R is selected from H, F, Cl, Br, OH, NH2, COOH, Me, CF3, CHF2, CH2F, 3. The compound according to claim 1 or 2, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl or 5-6 membered heteroaryl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are optionally substituted with 1, 2 or 3 R groups.

4. The compound according to claim 3, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from Me, 5. The compound according to claim 1 or 2, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: L1 is selected from a single bond, -CH2- or -CH2CH2-, wherein -CH2- and -CH2CH2- are optionally substituted by 1 or 2 R.

6. The compound according to claim 5, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: L1 is selected from a single bond, -CH2- or -CH2CH2-.

7. The compound according to claim 4 or 6, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from Me, 8. The compound according to claim 1 or 2, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: L2 is selected from a single bond, -CH2- or -CH2CH2-, wherein -CH2- and -CH2CH2- are optionally substituted by 1 or 2 R; L3 is selected from a single bond, -CH2- or -CH2CH2-, wherein -CH2- and -CH2CH2- are optionally substituted by 1 or 2 R.

9. The compound according to claim 8, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: L2 is selected from a single bond, -CH2- or -CH2CH2-; L3 is selected from a single bond, -CH2- or -CH2CH2-.

10. The compound according to claim 1 or 9, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from 11. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from 12. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: L4 is selected from a single bond, -O- or -CH2-.

13. The compound according to claim 1 or 12, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from 14. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R 11 Selected from H, D or Me.

15. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R1 and R 11 Connected together to form a cyclopropane group.

16. A compound of the following formula, an optical isomer thereof or a pharmaceutically acceptable salt thereof, which is selected from 17. Use of the compound according to any one of claims 1 to 16, its optical isomer or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating diseases associated with APP2 activity or bradykinin.

18. The APP2 activity or bradykinin-related disease according to claim 17, which is selected from ischemic stroke, acute myocardial infarction, chronic heart failure, myocardial hypertrophy, diabetic microangiopathy, renal hypertension, diabetic nephropathy, renal ischemia-reperfusion injury, drug-induced renal injury, chronic kidney disease, atherosclerosis, and vascular restenosis.

Citation Information

Patent Citations

  • Dipeptide derivatives having a N-terminal 2-thiocyl group as vasopeptidase inhibitors

    CN1649893A

  • Thio-containing inhibitors of aminopeptidase p, compositions thereof and method of use

    WO2007032887A2

  • 4-fluoro-THIO-containing inhibitors of APP2, compositions thereof and method of use

    WO2016085530A1